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A B S T R A C T
Background
Men who have a radical prostatectomy (RP) for prostate cancer that does not involve lymph nodes, but extends beyond the prostate
capsule into the seminal vesicles or to surgical margins, are at increased risk of relapse. In men with these high risk factors, radiotherapy
(RT) directed at the prostate bed after surgery may reduce this risk, and be curative.
Objectives
To evaluate the effect of adjuvant RT following RP for prostate cancer in men with high risk features compared with RP.
Search methods
We searched the Cochrane Prostatic Diseases and Urological Cancers Specialised Register (23 February 2011), the Cochrane Central
Register of Controlled Trials, MEDLINE, EMBASE (January 1966 to February 2011), PDQ® (Physician Data Query) trial registry
databases for ongoing studies (2November 2010), reference lists from selected studies and reviews, and handsearched relevant conference
proceedings.
Selection criteria
Randomised controlled trials (RCT) comparing RP followed by RT with RP alone.
Data collection and analysis
Two authors independently assessed the studies for inclusion and bias and extracted data for analysis. Authors were contacted to clarify
data and obtain missing information.
Main results
We found three RCTs involving 1815 men. Adjuvant RT following prostatectomy did not affect overall survival at 5 years (RD (risk
difference) 0.00; 95% CI -0.03 to 0.03), but improved survival at 10 years (RD -0.11; 95% CI -0.20 to -0.02). Adjuvant RT did not
improve prostate cancer-specific mortality at 5 years (RD -0.01; 95% CI -0.03 to 0.00). Adjuvant RT did not reduce metastatic disease
at 5 years (RD -0.00; 95% CI -0.04 to 0.03), but reduced it at 10 years (RD -0.11; 95% CI -0.20 to -0.01). It improved local control
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at 5 and 10 years (RD -0.10; 95% CI -0.13 to -0.06 and RD -0.14; 95% CI -0.21 to -0.07, respectively), and biochemical progression-
free survival at 5 years and 10 years (RD -0.16; 95% CI -0.21 to -0.11 and RD -0.29; 95% CI -0.39 to -0.19, respectively). There
were no data for clinical disease-free survival. Adjuvant RT increased acute and late gastrointestinal toxicity [do you have the rd for
this?], urinary stricture (RD 0.05; 95% CI 0.01 to 0.09) and incontinence (RD 0.04; 95% CI 0.01 to 0.08). It did not increase erectile
dysfunction or degrade quality of life (RD 0.01; 95% CI -0.06 to -0.26), but with limited data.
Authors’ conclusions
Adjuvant RT after RP improves overall survival and reduces the rate of distant metastases, but these effects are only evident with longer
follow up. At 5 and 10 years it improves local control and reduces the risk of biochemical failure, although the latter is not a clinical
endpoint. Moderate or severe acute and late toxicity is minimal. There is an increased risk of urinary stricture and incontinence, but
no detriment to quality of life, based on limited data. Given that the majority of men who have undergone a RP have a longer life
expectancy, radiotherapy should be considered for those with high-risk features following radical prostatectomy. The optimal timing is
unclear.
P L A I N L A N G U A G E S U M M A R Y
Radiotherapy after surgery for prostate cancer
Surgical removal of the prostate has a high chance of cure when prostate cancer is confined to the prostate. High-risk features (ie, cancer
that has spread through the capsule surrounding the prostate into the nearby seminal vesicles or to the edge of the surgical specimen)
found at the time of surgery increase the risk of the cancer recurring. Recurrence of cancer might show up as an abnormal blood test
(increased prostate-specific antigen (PSA)), local recurrence at the site of the prostate, or distant spread (most commonly to bones).
Radiotherapy, using external X-rays directed where the prostate was in the pelvis, has the potential to kill any prostate cancer cells left
behind, and improve the chance of cure. On the other hand, it may cause problems with bladder, bowel or sexual function. In some
men it may be futile if the prostate cancer cells have already spread beyond the pelvis. This review looked at whether radiotherapy given
after surgery for prostate cancer with these high risk features was effective in reducing the risk of prostate cancer recurring, whether it
made men live longer, and what the side effects were.
One trial with longer follow up (more than 10 years) showed improved survival with adjuvant radiotherapy but this improvement did
not exist at 5 years follow up. Radiotherapy reduced the number of men whose cancer spread to other parts of the body (metastases). We
found that radiotherapy improved local control in the prostate bed and did reduce the risk of cancer recurring. Radiotherapy reduced
the number of men with an abnormal PSA blood test, but the importance of this is uncertain. Radiotherapy does increase the risk of
side effects, (mostly mild) affecting bladder and bowel function.
It is not clear from these studies whether it is better to give radiotherapy immediately after surgery when these high risk features are
present, or whether it would be just as good watching for a time, and only giving radiotherapy once the PSA blood test starts to rise.
This is the subject of ongoing studies. Radiotherapy after radical prostatectomy should be considered if high risk features are present,
but the optimal timing is unclear.
B A C K G R O U N D
Globally, prostate cancer is the second most common malignancy
diagnosed inmen, with 903,500 estimated new cases worldwide in
2008 (Jemal 2011). It is the second most common cause of death
after lung cancer in theUnited States (Jemal 2010)). The incidence
has increased over the last few decades, largely due to the increasing
use of prostate specific cancer antigen (PSA) screening. This has
also led to an increase in the proportion of men diagnosed with
prostate cancer who have clinically localized disease (Cooperberg
2004).
The natural history of prostate cancer varies considerably. Prostate
cancer may behave aggressively, causing significant morbidity and
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death. For many men, however, the disease has an indolent course.
Given this, and the fact that prostate cancer occurs more often
in older men in whom life threatening co-morbid conditions are
more common, many men die with prostate cancer rather than
from it. Appreciation of the variable behavior of prostate cancer
has lead to considerable debate about optimal treatment.
There are a number of valid treatment options for men with local-
ized prostate cancer (clinically confined to the prostate). These in-
clude RP, external beam radiotherapy (EBRT), interstitial prostate
brachytherapy (radiation therapy delivered directly to the prostate,
either using permanently implanted radioactive seeds or tempo-
rary catheters containing a radiation source), hormonal therapy,
combinations of these, active surveillance, or observation.
There is evidence from randomised trials that radical prostatec-
tomy reduces the risk of distant metastasis and death from prostate
cancer compared to observation in men with prostate cancer de-
tected primarily by methods other than PSA testing (Bill-Axelson
2011). No randomised trials have compared radical prostatectomy
with contemporary radiotherapy, although large single and multi-
institutional trials suggest similar 5 and 10-year survival (Kupelian
2004; Kupelian 1997a). For each man the choice of treatment de-
pends on consideration of tumour, patient and treatment-related
factors. Tumour-related factors, such as PSA and Gleason score,
help to predict the natural history of the disease. Patient-related
factors, including co-morbid conditions and life expectancy, may
help to predict whether a man’s cancer is likely to cause bother in
his lifetime. Men also need to consider that treatments differ in
their effect on urinary, sexual and bowel functioning.
Radical prostatectomy is a surgical procedure which involves the
removal of the entire prostate gland with seminal vesicles and
the ampulla of the vas deferens. Depending on the characteristics
of the tumour and the man’s sexual function, this may involve
sparing of the neurovascular bundle, which increases the likelihood
of preserving potency. Lymph node dissection may be performed
if the risk of lymph node involvement is high, and if nodes are
positive, the prostate would not necessarily be removed.Menmost
suitable for radical prostatectomy are those with a life expectancy
of at least 10 years with disease that does not extend beyond the
prostate capsule.
After radical prostatectomy, if all normal and malignant prostate
tissue is removed, PSA levels should fall to undetectable levels by
the sixth week postoperatively. Even in appropriately selectedmen,
up to a third undergoing radical prostatectomy will experience
PSA failure (biochemical progression), with persistently detectable
or rising postoperative levels, within 10 years (Amling 2000; Han
2003; Hull 2002; Pound 1999; Roehl 2004; Ward 2003). PSA
failure may reflect residual local disease, distant metastatic disease,
or both. PSA failure predicts a higher risk of clinical failure and
death from prostate cancer. Nearly two-thirds of men with PSA
failure after radical prostatectomy who do not receive salvage ther-
apy develop metastatic disease within 10 years. The median sur-
vival for men who develop metastatic disease is less than 5 years
(Pound 1999).
Factors predicting a higher risk of relapse after radical prostatec-
tomy have been identified. These include a high preoperative PSA
(> 10 ng/mL (nanograms/millilitre), a short PSA doubling time
(PSADT), and pathological factors such as a high Gleason grade
(> 7), extracapsular extension, invasion of the seminal vesicle, pos-
itive margins, and lymph node involvement (Epstein 1996; Han
2003; Kausik 2002; Kupelian 1997b; Roehl 2004; Swindle 2005).
These factors differ in their relative effect on the risk of local as op-
posed to distant relapse.While lymph node metastases and a short
PSADT increase the risk of the development of distant metas-
tases, positive margins, extra-capsular spread and seminal vesicle
invasion increase the risk of local relapse. There is randomised
trial evidence for improved survival for men with involved lymph
nodes who receive androgen deprivation therapy postoperatively
compared with patients in whom androgen deprivation therapy is
deferred until the time of distant metastases or symptomatic re-
currence (Messing 2006). The appropriate course of action for pa-
tients without involved lymph nodes but other high risk features is
unclear. The conventional strategy for those at risk of relapse after
radical prostatectomy is surveillance, with salvage therapy deferred
until biochemical or clinical relapse is identified.
’Salvage’ treatment refers to treatment of patients with detectable
postoperative PSA beyond 6 weeks with or without palpable local
disease, and may occur at any stage following radical prostatec-
tomy. The optimal salvage treatment is controversial. Although
treatment modalities, including hormonal therapy or chemother-
apy, may be used when relapse is identified, radiotherapy is the
only modality currently known to have the potential to cure for
menwith residual or recurrent disease localized to the radiotherapy
treatment volume. Single institution, retrospective studies have
shown that salvage external beam radiotherapy achieves durable
disease control with up to 50% of men treated at relapse free from
biochemical progression (Anscher 2000; Cadeddu 1998; Cheung
2005; Duchesne 2003; Pazona 2005; Pisanasky 2000; Stephenson
2004).
Description of the intervention
Adjuvant radiotherapy (treatment of the prostate with high energy
X-rays) has been used for patients following radical prostatectomy
with high risk features, such as extracapsular extension, seminal
vesicle invasion, or positive margins, to prevent recurrence. ’Adju-
vant’ treatment is therapy given after surgery in men with an un-
detectable PSA, who are not known to have residual or recurrent
disease, but deemed at high risk of microscopic residual disease.
Adjuvant radiotherapy to the prostate tumour bed can potentially
eradicate microscopic residual tumour in the periprostatic tissues,
allowing cure for thosemenwith isolated local residual disease. Re-
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cent randomised controlled data shows that adjuvant radiotherapy
significantly reduces the risk of PSA failure compared to surgery
alone with salvage at recurrence ( ARO; EORTC; SWOG). With
longer follow up SWOG has shown significant improvements in
metastasis-free survival and overall survival. Despite this, the use
of adjuvant radiotherapy remains controversial, because of the fol-
lowing.
1. Randomised trials of adjuvant radiotherapy following
radical prostatectomy have not uniformly identified significant
differences in metastasis-free survival, cancer-specific survival or
overall survival. While this may be due to inadequate follow up,
reflecting the time lag between biochemical failure and clinical
failure, not all men with PSA failure develop clinically evident
local or distant recurrence, or they may do so only after a very
long time. Not all patients with clinical progression die of
prostate cancer.
2. Some men with high-risk features who are observed will not
develop PSA failure, and would receive radiotherapy
unnecessarily if all at-risk men were treated adjuvantly.
3. Radiotherapy is associated with well recognized toxicity,
particularly in the postoperative setting where operative
morbidity may be exacerbated (Hu 2006). Urethral strictures and
the recovery of continence and potency are particular concerns.
4. Some men are at very high risk of distant metastatic disease,
so radiotherapy to the periprostatic tissues may be futile, and the
side effects of treatment unjustified.
5. Salvage treatment in the control arms of the
abovementioned randomised trials may have been sub optimal.
Retrospective evidence has shown that durable salvage is most
likely achieved if radiotherapy is given at the earliest
confirmation of biochemical relapse. A number of series have
shown that cure rates with postoperative salvage radiotherapy
steadily decline as the PSA rises (Cheung 2005; Duchesne 2003;
Nudell 1999; Maier 2004; Stephenson 2004). The timing of
salvage treatment was not specified in the large randomised trials.
Careful surveillance and early radiotherapy may be as effective as
adjuvant radiotherapy for high-risk patients.
Why it is important to do this review
The optimal approach for high-risk men following radical prosta-
tectomy is not clear. Adjuvant radiotherapy significantly improves
PSA failure, but there is inconsistent evidence that it prevents
metastases or prostate-cancer death. Routine adjuvant radiother-
apy may be overtreatment for many men. Existing studies have
not been adequately powered or may have inadequate follow up to
show survival differences. A systematic review and meta-analysis
is essential to make a reliable estimate of the effect of adjuvant
radiotherapy.
O B J E C T I V E S
To assess the effects of adjuvant RT for men with high risk prostate
cancer who have had radical prostatectomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT) comparing radical prostate-
ctomy followed by adjuvant radiotherapy with radical prostatec-
tomy alone.
Types of participants
Men with histologically confirmed invasive prostate adenocar-
cinoma without regional lymph node involvement or distant
metastatic disease (AJCC (American Joint Committee on Cancer)
T1 to T4 N0 M0), who have undergone radical prostatectomy.
Types of interventions
Radical prostatectomy followed by adjuvant radiotherapy was
compared with radical prostatectomy alone. Radiotherapy refers
to megavoltage external beam radiotherapy to a radical dose of at
least 60 Gray (Gy) (in 1.8 to 2.0 Gy fractions) or the biological
equivalent, to a volume that covers at least the prostate bed using
two dimensional, three dimensional CT planning, IMRT or novel
techniques. Trials using other therapy, such as androgen suppres-
sion therapy, could be included provided the additional therapy
was given in both treatment groups, such that the analysis of the
effect of radiotherapy was unconfounded.
Types of outcome measures
Primary outcomes
The primary endpoint was overall mortality.
Secondary outcomes
The secondary endpoints included:
1. prostate cancer-specific mortality;
2. clinical disease-free survival (defined as freedom from local
or distant disease);
3. metastasis-free survival (defined as alive, with no evidence
of distant disease);
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4. local recurrence-free survival (defined as alive with no
evidence of local recurrence);
5. biochemical progression-free survival;
6. adverse outcomes (radiation toxicity, specifically late
genitourinary (continence and potency) and bowel toxicity,
scored using trial specific instruments);
7. quality of life (scored using trial-specific instruments);
8. patient preferences.
Timing of outcome assessment
Outcomes were assessed at 5 and 10 years.
Search methods for identification of studies
See the Prostatic Diseases and Urologic Cancers Group’s methods
used in reviews.
The Cochrane Prostatic Diseases and Urological Cancers Group
specialized register was searched (details of search strategies used
by the group for the identification of studies and the procedure
used to code references are outline in the group’s module) on 2
June 2008. Studies coded as ’X’ and ’Y’ on the specialized register
were extracted for consideration.
No language or publication restrictions were applied.
Electronic searches
Our search strategy included an electronic search of MEDLINE
on OVID from 1966 to 23 February 2011, to identify all relevant
published randomised trials that compare radical prostatectomy
with radical prostatectomy followed by adjuvant radiotherapy for
prostate cancer.
MEDLINE search strategy (see ’Appendix 1’).
This search was modified for additional searches of the following
electronic databases:
• Cochrane Central Register of Controlled Trials (Central);
• EMBASE (search date to 23 February 2011);
• PDQ® (search for open and closed trials) (2 November
2010).
Searching other resources
The following databases were searched for ongoing trials:
• Current Controlled Trials Register: http://www.controlled-
trials.com (2 November 2010);
• European Organisation for Research and Treatment of
Cancer (EORTC): http://www.eortc.be (searched 2 November
2010);
• United Kingdom Research Co-coordinating Committee on
Cancer Research (UKCCCR): (2 November 2010);
• UK National Research Register of all NHS-funded research:
http://www.doh.gov.uk/research/nrr.htm (2 November 2010);
• National Cancer Institute, America:(2 November 2010);
• National Cancer Institute, Canada: http://
www.ctg.queensu.ca/ctg_home/htm;
• National Health and Medical Council of Australia: http://
www.ctc.usyd.edu.au/ (searched 30 November 2010).
Handsearching
Relevant conference proceedings were manually searched to iden-
tify eligible trials, including ASCO (American Society of Clinical
Oncology) 1995 to 2010), ASTRO (American Society for Ther-
apeutic Radiology and Oncology) (2001 to 2010), ESTRO (Eu-
ropean Society for Therapeutic Radiology and Oncology) (1990,
1993, 2002 to2010), AUA (AmericanUrologyAssociation) (2000
to 2010) and EUA (European Association of Urology) (2010).
Journal of Urology 1999 to 2000 inclusive, and 2010: 184 (1 to
3); 183 (1 to 6); 184 (1 to 3); 182 (1 to 6); 181 (1 to 6).
Reference lists
Citations from identified trials and review articles were checked.
Correspondence
Authors and researchers were contacted to determine if they were
aware of other relevant studies.
Data collection and analysis
Selection of studies
All authors (TD, BH and ML) checked the titles and abstracts
retrieved. Each author independently assessed the full text of stud-
ies relevant to this review. Disagreements were resolved through
discussion.
Data extraction and management
Two authors (TD and BH) independently extracted data, with
disagreements resolved by discussion. Where possible we extracted
the following data: PSA prior to randomisation; pathological fac-
tors, including Gleason score, the presence of extra-capsular exten-
sion, seminal vesicle invasion, and positive margins; radiotherapy
data, including total dose, dose per fraction, and volume.Data was
checked and entered into RevMan 5.1.22 for statistical analysis.
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Assessment of risk of bias in included studies
The quality of each study and the subsequent risk of bias were
assessed independently by 2 reviewers (TD, BH) and ’Risk of
bias’ tables were constructed. ML reviewed the ’Risk of bias’ tables
and any differences in opinion were resolved through discussion.
When there was insufficient detail about the studymethod, further
information was sought from the authors.
Measures of treatment effect
We used the intention-to-treat principle to analyse data from the
included trials.
Dichotomous data
Dichotomous outcomes were presented as risk differences (RD)
with 95% confidence intervals (CI) for individual trials (Deeks
2002). The findings of each study were discussed and if deemed
appropriate and feasible, data were pooled. Where results were
significant, the absolute risk (DR) was calculated and the number
needed-to-treat (NNT) to prevent or produce the relevant out-
come (McQuay 1997).
Continuous data
Continuous data was dichotomised in the reports. In future up-
dates, where continuous variables (such as quality of life) are avail-
able, we will use recommended methods to collect and combine
the data. We will use the mean difference method, unless different
scales are used in the trials, in which case we will use a standard-
ized mean difference to summarize the data (Deeks 2002). [this
dichotomised continuous data needs to be explained]
Dealing with missing data
When data could not be extracted from the text, or statistics were
missing, the authors of the original articles were contacted to ob-
tain the necessary information.
Assessment of heterogeneity
Heterogeneity (clinical and methodological diversity) were as-
sessed both visually and statistically using the Chi2 test of het-
erogeneity and the Higgins I2test (Higgins 2002; Higgins 2003).
When heterogeneity was identified, reasons for it were explored
and caution in the interpretation of our results was emphasized.
We sought to reduce publication bias through our previously de-
scribed search methods and by contact with authors and experts
in the field.
Data synthesis
We used Mantel-Haenszel methods to calculate pooled results
(when it was appropriate to do so) and determined a weighted av-
erage treatment effect by using the fixed-effect model to combine
results (Greenland 1985; Mantel 1959).
In ARO, three different analyses were reported (see ’Figure 1’):
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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1. ITT1 - including all patients randomised according to
intention to treat;
2. ITT2 - excluding those patients who did not achieve an
undetectable PSA;
3. ITT3 - per protocol analysis.
We analysed the data using ITT1 for the outcome biochemical
relapse, all other outcomes fromAROused ITT2, as data for other
outcomes not reported by trial arm (ARO).
Where continuous variables were dichotomised (proctitis/ rectal
bleeding, urethral stricture), the fixed-effect model was used to
combine results. Where continence was reported using Interna-
tional Incontinence Scale (ICS) (see ’Table 1’), results were di-
chotomised, into grade 0 (dry) versus any higher grade of incon-
tinence (EORTC). Other continuous variables were not able to
be combined. As data from a single study was available, figures
for the text were reported. In future updates, it may be possible
to use the mean difference or the standardised mean difference to
analyse the data.
Subgroup analysis and investigation of heterogeneity
We were not able to do subgroup analysis other than by length of
follow up ( 5 years versus 10 years). If sufficient data is available
for future updates we may perform subgroup analyses to inves-
tigate whether the effect of postprostatectomy radiotherapy dif-
fers depending on radiation dose (greater than 60 Gy), measures
of tumour risk classification - including PSA at baseline, tumour
stage, the presence of extracapsular spread, seminal vesicle inva-
sion or positive margins - and histological grade and according to
the timing of salvage radiotherapy in the control arm. [I believe
you could expand this para and give the cut points for all these
categories]
Sensitivity analysis
We performed two sensitivity analyses: the first was by length of
follow up (5 years (ARO; EORTC) versus 10 years (SWOG)); the
second was to examine the two data sets presented in ARO. For
the outcome of biochemical relapse, they presented the results for
all men randomised (ITT1), and for only those men who achieved
an undetectable PSA postprostatectomy (ITT2). The rest of the
outcomes in ARO were derived from ITT2, so further sensitivity
analyses were not possible.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Our search strategy identified 2105 references. Screening of titles
and abstracts identified 33 potentially eligible reports. Five of these
(NCT00541047; NCT00860652; NCT00667069; Parker 2007;
Parker 2007a refer to three ongoing studies (NCT00667069;
RADICALS; RAVES) described in ’Characteristics of ongoing
studies’. The remaining 28 reports ( Abi Aad 1993; Bolla 2002;
Bolla 2004; Bolla 2004a; Bolla 2005; Bolla 2007; Collette
2005; Davis 2002; Elias 1997; Jani 2005; Moinpour 2008;
Swanson 2007; Swanson 2008; Swanson 2009; Thompson 2006;
Thompson 2009; Tombal 2006; VanCangh 1998 ; VanDerKwast
2006; Van der Kwast 2006a; Van der Kwast 2007;Wiegel 1998;
Wiegel 2008a; Wiegel 2005; Wiegel 2007; Wiegel 2007a; Wiegel
2009; Zurlo 2002) related to three randomised controlled tri-
als (ARO; EORTC; SWOG). Two excluded studies (Elias 1997;
Jani 2005) (see ’Excluded studies’). The three randomised con-
trolled studies reported at different times with different durations
of follow up (ARO; EORTC; SWOG). These are described in
’Characteristics of included studies’. The most recent publications
report results with a median follow up of 53 months (ARO), 60
months (EORTC) and 12.5 years (SWOG). In all three trials,
men were randomised postoperatively to a control arm of observa-
tion, or an experimental arm of external beam radiotherapy (ARO;
EORTC; SWOG).
Included studies
Design
All three trials were randomised controlled trials (ARO; EORTC;
SWOG) (see ’Characteristics of included studies’).
Sample sizes
The three trials included in this review randomised a total of 1815
men, including 385 men in ARO, 1005 men in EORTC and 425
men in SWOG.
Setting
In all trials men were recruited from multiple centres, from Ger-
many (ARO), Europe (EORTC), andUSA andCanada (SWOG).
Participants
All studies included men who had radical prostatectomy for
prostate adenocarcinoma with no lymph node or distant metas-
tases (N0M0), with one or more of the following pathological
risk factors: extracapsular extension; seminal vesicle invasion or
positive margins (ARO; EORTC; SWOG). Lymph nodes were
assessed by pelvic lymph node dissection in men recruited to
EORTC and ARO, and in SWOG in men recruited prior to June
1995. After this those considered at low risk of pelvic lymph node
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metastases ((1) clinical stage T1a or T2a, GS (Gleason score) 2
to 6 and PSA < 10 ng/mL (nanograms per millilitre), (2) stage
T1b-c, GS 2 to 5, and PSA < 10 ng/mL, (3) stage T2b, GS 2 to
6 and PSA < 6 ng/mL and (4) stage T2c, GS 2 to 6, and PSA
< 4 ng/mL) did not require pelvic lymphadenectomy. All men in
the three studies had a negative bone scan to exclude distant bony
metastatic disease.
The SWOG trial specified that men who had total urinary incon-
tinence postoperatively, persistent urinary extravasation, pelvic in-
jury or intraoperative rectal injury were excluded. ARO specified
that men had no major voiding problems postoperatively.
Androgen deprivation therapy prior to surgery (neoadjuvant hor-
monal therapy) was permitted in all three trials, but was received
by a minority of men in each trial (8% to 12%), and in similar
numbers in each treatment arm.
An undetectable PSA prior to randomisation was not required in
any of the studies.
Interventions
In all three trialsmenwere randomised postoperatively to a control
arm of observation, or an experimental arm of adjuvant RT (ARO;
EORTC; SWOG).
In ARO,men were randomised immediately postoperatively.Men
whose postoperative PSA became undetectable (< 0.1 ng/mL)were
treated according to their allocation. Those in the experimental
arm received external beam radiotherapy, starting within 6 to 12
weeks of surgery, to a dose of 60 Gy in 30 fractions, to a volume
that included the surgical limits ’from the seminal vesicles, marked
with clips intraoperatively, to the apex’. Men whose PSA did not
become undetectable were excluded and immediate radiotherapy
was given. The dose given to these men was not specified.
In EORTC men randomised to the experimental arm received
external beam radiotherapy to a dose of 60 Gy in 30 fractions,
starting within 16 weeks of surgery. A two phase technique was
used. In phase one 50 Gy in 25 fractions was given to a volume
“that included the surgical limits from the seminal vesicles to the
apex” with a margin, and a 10 Gy boost was used to treat the
previous limits of the prostate.
In SWOG the experimental arm received 60 to 64 Gy in 30 to 32
fractions, starting within 17 weeks of surgery (randomised within
16 weeks of surgery and starting radiotherapy within 10 days
of randomisation). The “prostatic fossa and paraprostatic tissues”
were treated.
Outcomes
ARO study
In ARO the primary outcome was biochemical progression free
survival, defined as “two consecutive increases above the detection
limit of the respective PSA assay used”. All men whose PSA did
not become undetectable were considered failures from the time
of randomisation. The secondary endpoints were metastasis free
survival, overall survival and acute and late toxicity. No distinc-
tion in the report is made between acute and late toxicity. Urinary
incontinence was not assessed in ARO as it was not part of the
RTOG/EORTC toxicity scoring system. Median duration of fol-
low up was 53.7 months (ARO).
EORTC study
The primary endpoint of the EORTC study was also biochemi-
cal progression-free survival. When the trial started the primary
endpoint was local recurrence, but this was subsequently changed
to clinical progression-free survival, and then to biochemical pro-
gression-free survival on the basis of “evolving urological practice”.
Secondary endpoints were clinical progression free survival, local
recurrence, and acute and late toxicity. Although not specified in
the protocol, overall survival was analysed. For acute toxicity (oc-
curring at less than six months post-treatment), the WHO scor-
ing system was used (a five point scale) (EORTC). For late tox-
icity, the EORTC/RTOG scoring system was used (a five point
scale) (’Table 2’) (EORTC). Quality of life and sexual function
were not assessed. Urinary incontinence was not evaluated in the
entire cohort as it was not part of the RTOG/EORTC toxicity
scoring system (EORTC). A subset of 100 men were evaluated for
continence. These men were a subset of those randomised in the
EORTC study, but all treated at a single institution. These men
had a validated modified pad weighing test (Bates 1983) using the
International Incontinence Scale (ICS) (see ’Table 1’) and an inter-
view. Baseline parameters do not suggest they differ significantly
from the remainder of men randomised in the study (EORTC).
Median duration of follow up was 60 months (EORTC).
SWOG study
The primary endpoint of the SWOG trial was metastasis-free sur-
vival. Secondary endpoints were biochemical relapse-free (RFS),
clinical recurrence free survival and time to hormonal treatment.
Although not specified in the protocol, overall survival was anal-
ysed. Complications, including rectal toxicity (proctitis or bleed-
ing), urethral stricture or total urinary incontinence were recorded.
Acute versus late complications are not clearly defined, and toxic-
ity was not graded. Median duration of follow up was 12.7 years
(SWOG).
Two hundred seventeen of four hundred twenty-five (217/425)
men were enrolled in a companion health related quality of life
study (HRQL). The trial was activated in August 1988. Men reg-
istered after February 1990 provided baseline HRQL, unless they
required translation. A validated Spanish translation was available
in 1995. HRQOL was evaluated at baseline (prior to randomisa-
tion), at 6 weeks, 6 months and annually to 5 years. Bowel func-
tion and genitourinary -specific symptom items were developed
(’Table 3’). These were validated through pilot testing (Moinpour
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1991; Rodriguez 1988), and have been shown to be sensitive to
change with time and treatment arm (Moinpour 1998).Outcomes
for bowel function, genitourinary-specific symptoms and global
HRQLwere reported as binary outcomes, recorded as present with
a score of ≥ 3 for bowel and genitourinary-specific symptoms and
< 5 for global HQRL as cut points. The clinically significant dif-
ference was defined as a ≥ 15% difference between the treatment
arms. Although men enrolled in the ancillary study of HRQL
were more likely to be African-American (24% versus 14%; P =
0.01), and less likely to have had preoperative hormone therapy,
they were not significantly different with respect to other baseline
factors (SWOG).
Differences between studies
A major difference in study design was that ARO randomised
patients immediately postoperatively and excluded patients from
their allocated treatment arm if they did not achieve an unde-
tectable PSA within 6 weeks. They performed three separate anal-
yses: by intention to treat, according to their initial allocation
(ITT1); after exclusion of those men who did not achieve unde-
tectable PSA (ITT2); and according to actual treatment received
(ITT3).
Of relevance to the calculation of biochemical failure, the trials
differed in:
1. the proportion of men for whom a postoperative PSA was
recorded (In EORTC, a postoperative PSA was recorded in
99.4% (999/1005) of all men. In SWOG, a postoperative PSA
value was recorded for 88% (376/425) of men randomised. In
ARO, a postoperative PSA value was available for all patients
(100%));
2. the definition of nadir (see ’Table 4’);
3. the proportion of men whose PSA became undetectable
postoperatively (achieved nadir) (In EORTC PSA was measured
and undetectable (defined as < 0.2 ng/mL), in approximately
90% of men in each arm (EORTC). In SWOG the PSA was
undetectable (< 0.2 ng/mL) postoperatively in 249 (66.2%) of
376 men who had a postoperative PSA recorded (SWOG). In
ARO all the men analysed for biochemical relapse had
undetectable PSA postoperatively (defined as ≥ 0.1 ng/mL)
(ARO). See ’Table 5’. Conversely: in ARO 78/388 (20%) of men
randomised the PSA remained detectable postoperatively. These
men were considered to have progressed, and received
radiotherapy, as per the study design (ARO). In SWOG 127/347
(33%) did not achieve PSA ≤ 0.2 ng/mL (SWOG). Ten per cent
(108/1005) of men in EORTC did not nadir postoperatively)
(see ’Table 5’));
4. the definition of biochemical relapse (In EORTC
biochemical failure was defined as a rise of > 0.2ng/mL over the
lowest postoperative value measured on three occasions at least
two weeks apart, and was calculated for all randomised patients
(EORTC). In SWOG it was defined as the first occurrence of a
PSA of > 0.4 ng/mL (SWOG). In ARO it was defined as two
consecutive rises in PSA (ARO))
5. the groups in whom that was calculated (In SWOG
biochemical relapse was assessed in 347 men with a postoperative
PSA ≤ 0.4 ng/mL (approximately 80% of men in each
treatment arm) (SWOG). In ARO biochemical failure was
calculated in two ways: ITT1 in all men randomised assuming
that those who did not achieve an undetectable PSA
postoperatively failed from the time of randomisation, and
ITT2, in 310/388 men (80%) who did achieve an undetectable
PSA postoperatively. In EORTC all men were included in
analysis of biochemical relapse.).
Toxicity reporting
In ARO acute radiation toxicity was scored according to the
RTOG scale (’Table 6’), and late toxicity according to the RTOG/
EORTC late scoring scale (’Table 2’). As continence and potency
are not included in this scoring system they were not assessed. The
reported results do not distinguish between acute and late events.
In SWOG the incidence of “total urinary continence” (defined as
no ability to control urinary leakage), urethral stricture and “rectal
complications” were measured, but no scoring system was used,
and the timing of the assessments is unclear (SWOG). The SWOG
quality of life sub study assessed urinary frequency, bowel move-
ment tenderness and urgency, and erectile dysfunction (’Table 3’).
In EORTC acute toxicity was measured using the WHO scoring
scale, and late toxicity using the RTOG/EORTC scoring scale
(’Table 2’). Urinary continence was assessed in a subset of 100
men from a single institution. Potency was not assessed.
Central pathology review was performed in all patients in ARO
and 311/425 (73%) of men in SWOG, but not in EORTC.
The dose given for salvage radiotherapy in the EORTC trial was
recommended (70 Gy in 35 fractions, with or without an LHRH
agonist), but was not specified in the ARO or SWOG trials.
Quality assurance for RTwas conducted for those men in EORTC
and SWOG but not reported in ARO.
Risk of bias in included studies
Allocation
Randomisation was performed centrally for all studies (ARO;
EORTC; SWOG). Allocation sequences were generated by using
computer generated lists with permuted blocks of randomly vary-
ing size per stratum in ARO. This was concealed (confirmed by
personal communication) (Morgan 2008). EORTC used a min-
imisation technique and SWOG did not indicate the method of
sequence generation. The randomisation process was unlikely to
be a source of bias in any of the trials (’Figure 1’).
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Blinding
See ’Characteristics of included studies’.
Patients and outcome assessors were not blinded to treatment al-
location. This was stated for SWOG and assumed for ARO and
EORTC.
Objective outcomes
Lack of blinding was unlikely to have introduced bias in the as-
sessment of overall survival, given the objective nature of this out-
come.
With regard to PSA failure, the time intervals for PSA tests were
prespecified, and therefore it is unlikely that lack of blinding in-
troduced bias (ARO; EORTC; SWOG).
There may have been some risk in the assessment of distant
metastatic disease if there was more frequent radiological inves-
tigation in patients who did not receive adjuvant radiotherapy
(ARO; EORTC; SWOG). Although information regarding the
frequency of investigations was not available, we felt that the risk
of bias from this was low.
Subjective outcomes
In EORTC, local recurrence was assessed usingDRE (digital rectal
exam).Given the subjective nature of this procedure, there is a high
risk of bias in the absence of personnel blinding. Confirmation of
local recurrence is best achieved with biopsy.
Lack of patient and assessor blinding may have had an effect on
reporting of both acute and late toxicity, with a bias in favour of
the observation arms in all three trials (’Figure 1’). We felt the risk
of bias was unclear in ARO and EORTC. In SWOG recording of
toxicity was neither graded nor pre-specified, and therefore there
was greater potential for toxicity recording to be influenced by the
interests or opinion of the involved clinician, increasing the risk
of bias, and therefore we judged that there was a high risk of bias
(SWOG) (’Figure 1’).
Incomplete outcome data
As mentioned above, the trials differed in the proportion of men
included in the analysis of biochemical failure, because of differ-
ing trial design. In EORTC a postoperative PSA was recorded for
nearly all men, and all men were included in the analysis of bio-
chemical failure. In ARO in ITT1 all men are included, but in
ITT2, those men who did not achieve undetectable PSA postop-
eratively were excluded. This makes data reported on the ITT2
analysis at high risk of bias; this includes the following outcomes:
overall survival, distant metastases and urethral stricture . We per-
formed a sensitivity analysis of both groups (ITT1 and ITT2) for
the outcome biochemical relapse. Given that ITT3 is not accord-
ing to randomised allocation there is significant risk of bias, and
this analysis has not been used in our summary statistic. In SWOG
approximately 20% of men were excluded from analysis of bio-
chemical failure in each arm, largely due to changing practice over
time. Given that proportions were similar, and the reason for ex-
clusion was similar, bias is unlikely.
With respect to toxicity reporting, a sub study of quality of life
outcomes in men recruited to SWOGwas reported. Although the
analysis included only half of total number of men recruited to
SWOGforwhombaseline quality of life datawas available, the au-
thors reported no significant difference in baseline characteristics
between the two treatment arms, or between the men included in
the quality of life sub study and those men who were not (’Figure
1’).
Selective reporting
For ARO, all outcomes reported in the paper had been specified in
the methods section. Overall survival, distant metastases and local
control are not reported for the entire cohort of randomised men,
which increases the risk of bias for these outcomes. Biochemical
relapse is reported for the entire cohort of randomised men. The
toxicity reporting is unclear, as it is not possible to distinguish
whether acute or late toxicity is reported in the ARO trial. In
both SWOG and EORTC, overall survival was reported despite
not being specified in the methods, but given the objective nature
of this outcome, bias is unlikely. There were insufficient details
available tomake a judgement aboutwhether therewas incomplete
outcome data for the three trials (ARO; EORTC; SWOG) (’Figure
1’).
Other potential sources of bias
Early stopping occurred in EORTC based on O’Brien-Flemming
stopping rule (EORTC). They reported their planned sample size
(1000), and randomised 1005 men. The trial was stopped by an
independent data monitoring committee when the pre-specified
P value of < 0.02 was reached. Although the treatment effect size
was large: (HR 0.48; 0.37, 0.62; P < 0.0001), this represented
365 events. Early stopping is unlikely to have introduced bias,
therefore we judged the risk of bias to be low (EORTC) (’Figure
1’).
Effects of interventions
Results are presented as risk differences (RD), with the RD < 0
evidence of a benefit to the experimental arm. The fixed-effect
model was used to pool results where appropriate.
Primary outcome
Overall survival
We studied 300 deaths in 1737 men.
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Adjuvant RT postprostatectomy did not improve survival at 5
years: (RD -0.00; 95% CI -0.03 to 0.02; P = 0.95) There was
no heterogeneity detected (P = 0.41, I2 = 0%) (ARO; EORTC)
(’Analysis 1.1’).
Adjuvant RT postprostatectomy did improve survival at 10 years:
RD -0.11 (95%CI -0.20 to -0.02; P = 0.02) (SWOG). Testing for
heterogeneity was not applicable. NNT = 10: it is expected that
one less person will die (from any cause) by 10 years for every ten
men who have prostate cancer with high risk features and receive
postprostatectomy RT (’Analysis 1.1’).
Secondary outcomes
Prostate cancer-specific mortality
Adjuvant RT did not improve prostate cancer-specific survival at
5 years (data from one study) (EORTC) (RD -0.01; 95% CI -
0.03 to 0.00) (’Analysis 1.2’).
Clinical disease-free survival
(defined as freedom from local or distant disease)
No data.
Metastasis-free survival
(defined as alive, with no evidence of distant disease)
Two hundred sixteen of seven hundred thirty-two (216/732) men
developed distant metastases.
Adjuvant RT postprostatectomy did not improve metastasis-free
survival at 5 years: (RD -0.01; 95% CI -0.03 to 0.0; P = 0.42).
There was no heterogeneity detected (ARO; EORTC; SWOG)
(’Analysis 1.2’).
Adjuvant RT postprostatectomy improvedmetastasis-free survival
at 10 years: RD -0.11 (95% CI -0.2 to -0.01; P = 0.03). Testing
for heterogeneity was not applicable (SWOG). NNT = 10: it is
expected that one less person will develop metastases by 10 years
for every 10 men who have prostate cancer with high risk features
and receive postprostatectomy RT (’Analysis 1.2’).
Local recurrence-free survival
(defined as alive with no evidence of local recurrence)
There were 154 local recurrences were reported in 1379 men.
Adjuvant RT postprostatectomy decreased local recurrence at 5
years: RD -0.10 (95% CI -0.13 to -0.06; P < 0.00001) (EORTC).
Testing for heterogeneity was not applicable. NNT = 10; it is
expected that one less person will develop local recurrence by 5
years for every ten men who have prostate cancer with high risk
features and receive postprostatectomy RT (’Analysis 1.3’).
Adjuvant RT postprostatectomy decreased local recurrence at 10
years: RD -0.14; 95% CI -0.21 to -0.07); P = 0.00001) (SWOG).
Testing for heterogeneity was not applicable. NNT = 8; it is ex-
pected that one less person will develop local recurrence by 5 years
for every 8 men who have prostate cancer with high risk features
and receive postprostatectomy RT (’Analysis 1.3’).
Biochemical progression-free survival
When all randomised men were studied (ITT1), biochemical pro-
gression-free survival improved with adjuvant RT at:
1. 5 years ((RD -0.15; 95% CI -0.20 to -0.11; P < 0.00001).
Heterogeneity was detected: P = 0.09, I2 = 66% (ARO;
EORTC) (’Analysis 1.4’). NNT = 7; it is expected that one less
person will develop biochemical relapse by 5 years for every
seven men who have prostate cancer with high risk features and
receive postprostatectomy RT.);
2. 10 years ((RD -0.29; 95% CI -0.39 to -0.19; P < 0.00001).
Testing for heterogeneity was not applicable (SWOG) (’Analysis
1.4’). NNT = 4; it is expected that one less person will develop
biochemical relapse by 10 years for every four men who have
prostate cancer with high risk features and receive
postprostatectomy RT.).
We performed a sensitivity analysis: when only those men whose
PSA nadired postprostatectomy (ITT2) (ARO) were studied, bio-
chemical progression-free survival improved with adjuvant RT at
5 years: (RD -0.18; 95% CI -0.23 to -0.13; P ≤ 0.00001) or 10
years:(RD -0.29; 95% CI -0.39 to -0.19). There was no hetero-
geneity detected: P = 0.69, I2 = 0% (ARO; EORTC) (’Analysis
1.5’).
Adverse outcomes
Nearly twenty-four per cent (51/214) men reported non-specific
adverse effects during follow up in the adjuvant RT arm compared
with 11.7% (25/211) men in the observation arm (SWOG). Non-
specific adverse effects during follow up (no time reported) were
more common after RT: RD 0.12 (95% CI 0.05 to 0.19; P =
0.001). Testing for heterogeneity was not applicable (SWOG).
NNT = 9: it is expected that one more person will develop non-
specific adverse effects for every ninemenwhohave prostate cancer
with high risk features and receive postprostatectomy RT.
Acute effects: (toxicity occurring within 90 days of
treatment)
Gastrointestinal toxicity
In the SWOG quality of life sub study “significantly more men
had tenderness and urgency with bowel movements at six weeks
in the adjuvant RT group” (47% versus 5%, no P value reported)
(SWOG). In EORTC 24/457 (5.3%) men having radiotherapy
had grade 3 diarrhoea.
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Genitourinary toxicity
Urinary frequency and dysuria
Urinary frequency was more common after RT in the 217/425
men in the SWOGquality of life sub study (a clinically significant
difference was defined as ≥ 15% difference between treatment
arms) (SWOG). This difference remained constant over time (see
’Characteristics of included studies’). In EORTC 15/457 (3.3%)
men reported WHO Grade III urinary frequency and 2/457
(0.4%) reported WHO Grade IV urinary frequency (EORTC).
5/457 (1.1%) reported WHO Grade III dysuria (EORTC).
Late effects:(toxicity occurring later than 90 days after RT)
Grade II or III late effects (genitourinary and gastrointestinal)
were more frequent after RT (no figures reported, P = 0.0005)
(EORTC). Grade III toxicity (genitourinary and gastrointestinal)
was increased at 5 years after RT: 4.2% versus 2.6%, P = 0.0726
(figures from text). No Grade IV toxicity was reported (EORTC).
Gastrointestinal toxicity
Rectal complications (proctitis and rectal bleeding)
Seven of two hundred fourteen (3.2%) of men who received ad-
juvant RT reported proctitis and rectal bleeding compared to 0/
211(0%) in the observation arm (SWOG). Proctitis and rectal
bleeding were more common after RT: RD 0.03 (95% CI 0.01
to 0.06; P = 0.01). Testing for heterogeneity was not applicable
(SWOG). NNT = 34: it is expected that one more person will
develop proctitis and rectal bleeding for every 34 men who have
prostate cancer with high risk features and receive postprostatec-
tomy RT.
“Tenderness and urgency of bowel movement” settled with time;
by 2 years the authors reported “little difference between groups”
(no figures or P value reported) (SWOG).
Genitourinary toxicity
Grade II genitourinary toxicity
Three of one hundred fifty-nine (3/159) (1.8%) men in the adju-
vant RT arm reported Grade II genitourinary toxicity compared
with 0/148 (0%) men in the observation arm (ARO).Grade II
genitourinary toxicity was not increased after RT: RD 2% (95%
CI -1% to 4%; P = 0.13). Testing for heterogeneity was not ap-
plicable (ARO).
Urethral stricture
Forty of three hundred seventy-three (40/373) (10%) (range 1.3%
to 17%) men had urethral strictures in the adjuvant RT arm com-
pared with 21/359 (5.8%) (range 0.7% to 9%) men in the obser-
vation arm (ARO; SWOG).
Urethral strictures at:
1. 5 years did not differ between the two groups ((RD 0.01;
95% CI -0.02 to 0.03; P = 0.6) (ARO). Testing for heterogeneity
was not applicable (’Analysis 1.5’));
2. 10 years were increased with adjuvant RT ((RD 0.08; 95%
CI 0.02 to 0.15; P = 0.01) (SWOG). Testing for heterogeneity
was not applicable. NNT = 13: it is expected that one more
person will develop urethral stricture for every 13 men (at 10
years) who have prostate cancer with high risk features and
receive postprostatectomy RT (’Analysis 1.5’)).
Urinary incontinence
Eighteen of two hundred sixty-two (18/262) (6.8%) (range 6% to
8%)menwho received adjuvantRT reported urinary incontinence
compared with 7/263 (2.6%) (range 2-2%) [check range] men in
the observation arm (EORTC; SWOG).
Urinary incontinence at:
1) 5 years was not increased for men who received adjuvant RT
((RD 0.06; 95% CI -0.02 to 0.15)RD 0.06; P = 0.15) (EORTC).
Testing for heterogeneity was not applicable (’Analysis 1.6’));
2) 10 years was not increased for men who received adjuvant RT
((RD 0.04; 95% CI -0.00 to 0.08; P = 0.07) (SWOG). Testing
for heterogeneity was not applicable (’Analysis 1.6’)).
Erectile dysfunction
The proportion of men with erectile dysfunction significantly de-
creased over time (P = 0.02), but did not vary significantly accord-
ing to treatment arm (P = 0.16), figures from text (SWOG).
Quality of life (scored using trial-specific instruments)
Global health related quality of life (GHRQL)
Fewer men who had RT reported normal GHRQL at six weeks:
RD -0.16 (95% CI -0.30 to -0.02; P = 0.02). Testing for hetero-
geneity was not applicable (SWOG).
The number of menwith normal GHRQL at 5 years did not differ
between the groups: RD 0.1 (95% CI -0.06 to 0.26; P = 0.21).
Testing for heterogeneity was not applicable (SWOG).
Patient preference
No data.
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D I S C U S S I O N
Summary of main results
In this review we found no overall survival benefit at 5 years for
men who have had prostatectomy for cancer with high-risk fea-
tures (positive margins, extra-capsular spread and seminal vesicle
invasion) treated with adjuvant radiotherapy postprostatectomy:
RD 0 (95% CI -0.03 to 0.02; P = 0.95). At 10 years however,
adjuvant RT postprostatectomy did improve survival: RD -0.11
(95% CI -0.20 to -0.02; P = 0.02) (’Analysis 1.1’).
Prostate cancer-specific mortality at 5 years was not improved by
adjuvant RT: (RD -0.01; 95% CI -0.03 to 0.00). For clinical
disease-free survival, there was no data.
Metastasis-free survival was not improved by adjuvant RT post-
prostatectomy at 5 years: (RD -0.01; 95% CI -0.03 to 0.01), but
was improved at 10 years: (RD -0.11; 95% CI -0.20 to -0.01; P =
0.03) (’Analysis 1.2’).
Adjuvant RT postprostatectomy decreased local recurrence at 5
years: (RD -0.10; 95% CI -0.13 to -0.06; P < 0.00001) and at 10
years: (RD -0.14; 95% CI -0.21 to -0.07; P = 0.00001) (’Analysis
1.3’).
Biochemical progression-free survival was decreased by adjuvant
postprostatectomy radiation therapy at 5 years:(RD -0.15; 95%
CI -0.20 to -0.11) and 10 years (RD -0.29; 95% CI -0.39 to -
0.19) (’Analysis 1.4’).
There was a significant increase in mild acute genitourinary and
gastrointestinal toxicity with adjuvant radiotherapy, and fewer
men reported normal global HRQOL at 6 weeks. There was also
a significant increase in the risk of late genitourinary and gastroin-
testinal toxicity with proctitis and rectal bleeding more common,
but tenderness and urgency settled with time, and little difference
was evident with time.
Urethral strictures at 5 years were not increased by adjuvant RT:
(RD 0.01; 95% CI -0.02 to 0.03) but strictures at 10 years were
increased with adjuvant RT:(RD 0.08; 95% CI 0.02 to 0.1; P =
0.01) (SWOG).
Urinary incontinence was not increased at 5 years for men who
received adjuvant RT: (RD 0.06; 95% CI -0.02 to 0.15; P = 0.15)
(EORTC) or 10 years for men who received adjuvant RT: (RD
0.04; 95% CI -0.00 to 0.08; P = 0.07) (SWOG).
Although erectile dysfunction significantly decreased with time (P
= 0.02), it did not vary according to treatment arm (P = 0.16,
figures from text) (SWOG). At 5 years the number of men with
normal GHRQL did not differ (SWOG).
Overall completeness and applicability of
evidence
Radical prostatectomy is frequently used for the treatment of lo-
calised prostate cancer (Cooperberg 2010). About one third ofmen
who have radical prostatectomy fail biochemically (PSA rises), and
are at risk of subsequent clinical failure (Pound 1999). Adjuvant
RT may improve cure rates after radical prostatectomy in men
who have isolated local residual disease. Men with prostate cancer
who choose radical prostatectomy want cure with preservation of
urinary continence and sexual function. Ideally, the addition of
postprostatectomy radiotherapy would improve their chance of
cure without adding significant morbidity. This review set out to
determine if the addition of postoperative radiotherapy for men
with high risk localised prostate cancer treated with radical prosta-
tectomy improved survival without significant toxicity or detri-
ment to quality of life. The comparison studied was: men with
early prostate cancer treated with radical prostatectomy and post-
operative adjuvant RT versus surgery alone.
Two of these trials started before the widespread use of PSA test-
ing. The common use of PSA testing (ad hoc or in screening pro-
grammes) means that contemporary practice would include men
with earlier stage disease and lower tumour burden. Despite this,
almost 50% of men having radical prostatectomy inmodern series
(even with PSA detected disease) will have cancer that extends be-
yond the prostate capsule, or positive margins (Karakiewicz 2005).
The term ’adjuvant’ radiotherapy following radical prostatectomy
describes radiotherapy given in the absence of measurable residual
prostate cancer based on an undetectable PSA level 6 weeks post-
operatively. In contrast the term ’salvage’ radiotherapy postprosta-
tectomy is used in men with PSA which is detectable or rising at
6 weeks postoperatively. As EORTC and SWOG were initiated
at a time when PSA was not widely used, not all participants in
the three studies achieved undetectable PSA levels postoperatively,
and therefore the intervention arms include patients treated adju-
vantly and for salvage.
The definition of an undetectable PSA was not uniform in the
included studies (ARO; EORTC; SWOG) (’Table 4’). The pro-
portion of men who did achieve an undetectable PSA and thus
were treated with adjuvant RT differed among the included stud-
ies (ARO; EORTC; SWOG) (’Table 5’). The inclusion of 313/
1769 (17%) men who did not nadir (achieve PSA ≤ 0.2 ng/dL
(nanograms/decilitre) may have diluted the effect that adjuvant
RT may have on the clinically important endpoints of overall and
metastasis-free survival. This difference in trial design may explain
in part the heterogeneity seen in biochemical relapse-free survival
at 5 years. This is supported by our sensitivity analysis incorporat-
ing ITT2 (which comprised only those menwho had undetectable
PSA postoperatively) (ARO).
The gold standard endpoint for evidence of clinical benefit is over-
all survival. We found an improvement in overall survival with
adjuvant radiotherapy at 10 years, but not 5 years. While the ab-
sence of an improvement at 5 years may reflect inadequate sample
size, the improvement evident with longer follow up would be
consistent with the variable and sometimes long natural history
of prostate cancer. For men with PSA failure after radical prosta-
tectomy the median time between biochemical failure and metas-
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tases is 8 years, and between metastases and death; 5 years (Pound
1999). SWOGreported that adjuvant radiotherapy postprostatec-
tomy improved survival: this study had significantly longer follow
up (12.5 years) than the other included studies, median follow up:
53.7 months (ARO) and 60 months (EORTC). The finding of
early reduction in local recurrence with delayed smaller improve-
ment in survival parallels the findings when adjuvant RT is used in
breast cancer. When RT is given after breast conservative surgery
or postmastectomy, local recurrence is reduced by two thirds, but
the smaller gain in survival (five percent) is not seen till after 10 to
15 years follow up. Given that the majority of men who undergo
radical prostatectomy would be expected to have a life expectancy
of at least 10 years, the benefit at 10 years should be relevant.
The development of metastatic disease is a clinically important
outcome; it increases the risk of developing symptoms, and of
dying from prostate cancer. The National Cancer Institute PSA
Working Group recommend that the development of metastases
be used to measure the clinical efficacy of therapy postprostatec-
tomy (Scher 2004).
Biochemical progression-free survival was increased by adjuvant
postprostatectomy RT. The clinical significance of this finding is
uncertain. The clinical relevance of PSA failure has been debated
(Jhaveri 1999). PSA failure universally antedates metastases and
prostate cancer death, but not all men who fail biochemically will
develop clinically evident disease, or die of their prostate cancer.
There may be a significant lag time between the development of
PSA failure and clinicallymeasurable or symptomatic disease. This
long natural history promotes the use of surrogate endpoints. Al-
though PSA is a sensitive marker for early treatment failure, given
the variable natural history, and competing risks for death in older
men, biochemical failure is not a validated surrogate endpoint for
prostate cancer specific survival or overall survival in metastatic
prostate cancer (Collette 2005). Its value in non-metastatic disease
has not been validated and does not predict survival in this setting
(Jhaveri 1999). These conclusions may not apply however in a
younger cohort of men with fewer competing risks.
Considerable variation in the definition of PSA failure adds to the
confusion. Cookson 2007 found up to 53 definitions of PSA fail-
ure following radical prostatectomy used in the literature. Defini-
tions vary in the cutoff used, and the need for confirmatory mea-
surements, or an increase. The most common was ≥ 0.2 ng/mL.
In 2007 the AmericanUrological Association recommended that a
value of≥ 0.2 ng/mL be accepted as the definition of biochemical
relapse post RP (confirmed with second specimen ≥ 0.2 ng/mL)
(Cookson 2007). The definition of what constituted biochemi-
cal relapse differed in the included studies (See ’Characteristics of
included studies’). This may have contributed to the heterogeneity
we found.
Comparisons of toxicity between adjuvant radiotherapy and
surgery alone were limited by a number of factors including:
1. Insufficient distinction between acute versus late toxicity in
both ARO and SWOG. While acute radiation effects (those seen
within 90 days of RT) may cause significant morbidity, they
often resolve with time after completion of radiotherapy. Late
radiation effects, however, are usually irreversible.
2. Aggregate toxicity rates were given, without distinction
between gastrointestinal and genitourinary side effects
(EORTC).
3. There was variation in the RT morbidity scoring systems
used.
4. Sexual function and continence following treatment was
not assessed (ARO; EORTC).
The American Urological Association Prostate Cancer Guideline
Update Panel reviewed reporting of erectile function outcomes
used in the literature (Burnett 2007).They found great variation
in the measurement of sexual function outcomes used, hinder-
ing useful comparisons between treatments. They recommended
use of a validated standardised scoring system, such as the Inter-
national Index of Erectile Function Questionnaire (IIEF) (Rosen
1997), to allow comparisons in future trials. Additionally there is
no consensus on the definition of incontinence.
There remain some unanswered questions:
1. Is early salvage radiotherapy as good as adjuvant radiotherapy?
The studies included in this review (ARO; EORTC; SWOG)were
not designed to compare adjuvant RT postprostatectomy with
salvage RT. Although salvage RT was encouraged for those men
randomised to observation who failed clinically or biochemically,
RT details were not specified in the protocol, and there were no
pre-defined triggers for instituting salvage. Thirty three per cent
(70/211) of men in the observation arm received salvage RT in
SWOG. PSA values before RT, within 6 months of commence-
ment were available for 65% and the median value was 1.0 ng/
mL. Forty one per cent (207/502) of men randomised to observa-
tion developed biochemical relapse in EORTC. Fifty four per cent
(113/207) of those men with biochemical relapse received salvage
RT (EORTC). In ARO 33 men who did not achieve undetectable
PSA postoperatively received RT. No details are reported about
salvage RT for the men (63/175) (36%) in the observation arm
who relapsed (ARO).
The success of salvage RT for men with biochemical relapse post-
prostatectomy in achieving PSA control is greatest when given
early, when the PSA is very low. This has lead to the concept of
’early salvage’ RT. More than half the men in the control arms in
the included studies did not fail biochemically, so did not need
salvage RT (ARO; EORTC; SWOG). PSA monitoring may allow
early identification of those men with residual disease confined to
the operative bed for whom RT is necessary. This approach avoids
unnecessary RT in those men who will not fail and delays RT.
This delay may allow recovery of continence and sexual function.
Three ongoing trials compare adjuvant RT postprostatectomy
with observation and early salvage (NCT00667069; RADICALS;
RAVES). RADICALS aims to randomise men postprostatectomy
(with PSA < 0.4 ng/mL) to immediate adjuvant RT or observation
with early salvage RT. RAVES compares immediate adjuvant RT
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postprostatectomy (PSA undetectable postoperatively) to imme-
diate adjuvant RT or early salvage. The triggers for salvage are pre-
specified (see ’Characteristics of ongoing studies’).NCT00667069
compares immediate RT postprostatectomy plus androgen depri-
vation (in men with PSA < 0.2 ng/mL) to early salvage (PSA <0.2
ng/mL) plus androgen deprivation.
2. What is the optimal radiotherapy dose, volume and technique?
Developments in RT delivery mean that the RT given in the in-
cluded studies may be sub-optimal by current standards. Two-di-
mensional planning was used in SWOG, 3D conformal RT was
used in ARO. Three dimensional (3D) conformal (fields shaped
to exclude normal tissues) and intensity modulated RT (IMRT)
(multi-beam RT which allows sparing of normal tissues) have be-
come the standard of care in the radiation treatment of prostate
cancer. These techniques allow sparing of dose to surrounding
normal tissues, reducing RT related toxicity, and allow dose esca-
lation in RT for the intact prostate (Cozzarini 2003; Dearnaley
1999). With modern RT techniques, it may be possible to deliver
the same or higher RT doses with less morbidity in the postprosta-
tectomy setting.
The volumes treated in the included studies are not clearly de-
scribed. The clinical target volume at risk can be difficult to de-
fine postprostatectomy. Published guidelines defining the clinical
target volume at risk now exist (Mickalski 2010; Mirabell 2007;
Poortmans 2007; Sidhom 2008; Wiltshire 2007); they were not
available when the men in the included studies were treated.
The radiation dose used in these studies (60 Gy in ARO and
EORTC, 60 to 64 Gy in SWOG) may be insufficient. A number
of retrospective trials have shown that lower doses, with varying
cutoffs between 60 and 70 Gy, are associated with higher rates of
biochemical failure in the adjuvant (PSA undetectable postoper-
ative PSA) and salvage setting (detectable PSA) (Cozzarini 2009;
Bernard 2010; King 2008; Tomita 2009; Valicenti 1998). Further
randomised trials are needed to determine the most effective dose.
Quality assurance was performed for EORTC and SWOG, but
not reported for ARO.
3) Are other adjuvant therapies required?
Postoperative RT can only be curative if residual or recurrent dis-
ease is localised to the volume treated. Failure after RT may re-
flect insufficient dose, but it can also represent distant metastatic
disease. Adjuvant androgen deprivation therapy (blocking the ac-
tion of testosterone) improves survival in menwith involved pelvic
nodes who have had radical prostatectomy (Messing 2006). Pro-
longed androgen deprivation after definitive radiation therapy im-
proves survival inmenwith high risk and locally advanced prostate
cancer (Bolla 2002; Pilepich 2001; Pilepich 2005). Given the ben-
efit in these settings, it has beenhypothesised that adjuvantRTplus
androgen deprivation postprostatectomy may benefit those men
who are node negative but have other high risk features. This hy-
pothesis is currently the subject of twoongoing trials (RADICALS;
NCT00949962) (see ’Characteristics of ongoing studies’).
Quality of the evidence
We included data from three studies with median follow up of 60
months (EORTC), 53 months (ARO) and 12.5 years (SWOG).
The studies included 1815 men who had radical prostatectomy
for prostate cancer. All three studies had pre-determined follow
up intervals and performed PSA levels at each visit (see ’Included
studies’). A test of funnel plot symmetry was not possible or ap-
propriate, as there were only three studies found (Cochrane Hand-
book) (Higgins 2008). The three included studies were of mod-
erate to high quality, except for the high risk of bias for subjective
outcomes which were not blinded.
Potential biases in the review process
The major potential sources of bias in all three trials related to
the lack of blinding for assessment of subjective outcomes. For
metastasis-free survival, the lack of blinding was a potential source
of bias, as unblinded investigators may have ordered bone scans
earlier and therefore introduced lead-time bias, shortening metas-
tasis-free survival. We thought there was high risk of bias in de-
termination of local recurrence (and subsequently also of clinical
recurrence, which includes local recurrence), particularly consid-
ering subjective nature of interpretation of DRE. Confirmation of
local recurrence is best achieved with biopsy.
Lack of patient and assessor blinding may also have had an effect
on reporting of acute and late toxicity, so we felt the risk of bias
was unclear. Patients having RT had more frequent assessment of
toxicity, and patient and assessors more likely to report toxicity
in RT arm. The information about continence was reported in a
subset of 100 men treated at a single institution, representing 100/
1815 (5.5%) men studied (EORTC).
There was high risk of bias from selective and incomplete outcome
reporting in one study (ARO), which made all outcomes other
than biochemical relapse at high risk of bias.
Agreements and disagreements with other
studies or reviews
Our findings are consistent with those ofMorgan 2008 and Roque
2008. They did both a systematic review and meta-analysis on
the same topic which included the same three trials (with shorter
follow up). Morgan 2008 excluded studies not published in En-
glish. This did not introduce language bias, as the three included
studies were all published in English. They reported no difference
in survival with adjuvant RT postprostatectomy: HR 0.91 (95%
CI 0.67, 1.22; P = 0.52) (Morgan 2008), P = 0.26 (Roque 2008).
They reported no difference in metastasis-free survival: HR =
0.75 (95% CI 0.55-1.02; P = 0.06) (Morgan 2008) (using figures
from the text) for one study (SWOG), P = 0.27 (Roque 2008).
They confirm our finding of improvement in biochemical RFS
with adjuvant RT postprostatectomy: HR 0.47 (95% CI 0.40,
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0.561; P < 0.00001) (Morgan 2008) and HR 0.37 (95% CI 0.29,
0.46; P < 0.00001) (Roque 2008). We found an improvement in
overall survival and metastasis free survival at 10 years, which may
be explained by the longer follow up.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Radiotherapy following radical prostatectomy in men with high
risk features should be considered for men who have a life ex-
pectancy of more than 10 years. The optimum timing (adjuvant
or early salvage) is unknown. Consideration should be given to
recruitment to a clinical trial in progress.
Implications for research
Studies designed to adequately address all-cause and prostate can-
cer-specificmortality are needed. Better information regarding pa-
tient related outcomes is desirable. Patient-reported toxicity and
quality of life related outcomes, (in particular: incontinence, po-
tency, sexual function and patient satisfaction) should be reported
and scored using validated scales. Clear description of volumes
treated, techniques, dose prescription and quality assurance are
required for RT trials. Ongoing trials are addressing the ques-
tion of whether adjuvant RT is better than early salvage (RAVES;
RADICALS) and the effect of the addition of androgen depriva-
tion to postprostatectomy RT (NCT00667069; RADICALS).
A C K N OW L E D G E M E N T S
Princess Alexandra Cancer Collaborative Group
R E F E R E N C E S
References to studies included in this review
ARO {published data only}
∗ Wiegel T, Bottke D, Steiner U, Siegmann A, Golz
R, Störkel S, et al.Phase III postoperative adjuvant
radiotherapy after radical prostatectomy compared with
radical prostatectomy alone in pT3 prostate cancer with
postoperative undetectable prostate-specific antigen: ARO
96-02/AOU AP 09/95. Journal of Clinical Oncology 2009;
27(18):2924–30. [: thomas.wiegel@uniklinik–ulm.de
(accessed 23 February 2011)]
Wiegel T, Bottke D, Willich N, Piechoto A, Siegmann M,
Stoekle M, et al.Phase III results of adjuvant radiotherapy
(RT) versus wait-and-see (WS) in patients with pT3 prostate
cancer following radical prostatectomy (RP) (ARO 96-02/
AUO AP 09/95). Journal of Clinical Oncology. 2007; Vol.
25:18S.
Wiegel T, Bottke D, Willich N, Siegmann A, Stoekle M,
Ruebe C, et al.Phase III results of adjuvant radiotherapy
versus “wait and see” in patients with pT3 prostate cancer.
International Journal of Radiation Oncology, Biology
Physics. 2007; Vol. 69, issue 3:S1062.
Wiegel TD, Bottke N,Willich H-J, Piechota R, SouchonM,
Stoeckle C, et al.Phase III results of adjuvant radiotherapy
(RT) versus “wait and see” (WS) in patients with pT3
prostate cancer following radical prostatectomy (RP) (ARO
96-02/AUO AP 09/95). Journal of Clinical Oncology 2005
Annual Meeting Proceedings. 2005; Vol. 23:16S.
EORTC {published data only}
Abi Aad AS, Opsomer RJ, Wese FX, Lorge F, VanCangh
PJ. Objective evaluation of continence after radical
prostatectomy. Journal of Urology. 1993; Vol. 145:235A.
Bolla M, Collette L, Blank L, Warde P, Dubois JB,
Mirimanoff RO, et al.Long-term results with immediate
androgen suppression and external irradiation in patients
with locally advanced prostate cancer (an EORTC study): a
phase III randomised trial. Lancet 2002;360(9327):103–6.
Bolla M, Van Poppel H, Collette L. Preliminary results for
EORTC trial 22911: radical prostatectomy followed by
postoperative radiotherapy in prostate cancers with a high
risk of progression. Cancer Radiotherapie 2007;11(6-7):
363–9.
∗ Bolla M, van Poppel H, Collette L, van Cangh P,
Vekemans K, Da Pozzo L, et al.Postoperative radiotherapy
after radical prostatectomy: a randomised controlled trial
(EORTC 22911). The Lancet 2005;366:572–8.
Bolla M, Van Poppel H, Van Cangh P, et al.Post-operative
radiotherapy (P-XRT) after radical prostatectomy (Px)
improves progression-free survival (PFS) in pT3N0 prostate
cancer (PC). International Journal of Radlation Oncology
Biology Physics. 2004a; Vol. 60:S186.
Bolla M, Van Popple H, Van Cangh P, et al.Does post-
operative radiotherapy (P-RXT) after radical prostatectomy
(Px) improve progression-free survival (PFS) in pT3N0
prostate cancer (PC)? (EORTC 22911). Proceedings of
Americal Society of Clinical Oncology Journal of Clinical
Oncology. 2004; Vol. 22:4504.
Collette L, van Poppell H, Bolla M, van Cangh P, Vekemans
K, Da Pozzo L, et al.Patients at high risk of progression after
radical prostatectomy: Do they all benefit from immediate
post-operative irradiation? (EORTC 22911). European
Journal of Cancer 2005;41:2662–72.
Davis JB, Reiner B, Dusserre A, Giraud JY, Bolla M,
EORTC. Quality assurance of the EORTC trial 22911. A
phase III study of post-operative external radiotherapy in
pathological stage T3N0 prostatic carcinoma: the dummy
16Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
run. Radiotherapy and Oncology. 2002; Vol. 64:65–73.
Tombal B, Scaillet P, Opsomer R, et al.Immediate external
beam radiation therapy (EBRT) after radical prostatectomy
(PCa): long-term influence on QOL, urinary and rectal
symptoms. Journal of Urology. 2006.
Van Cangh PJ, Richard F, Lorger F, et al.Adjuvant radiation
therapy does not cause urinary incontinence after radical
prostatectomy: results of a prospective randomised study.
Journal of Urology 1998;159:164–6.
Van Der Kwast TH, Bolla M, Van Poppel H, et al.Gleason
score and margin status are the strongest predictors for
benefit of radiotherapy after radical prostatectomy. Journal
of Urology. 2006.
Van der Kwast TH, Bolla M, Van Poppell H, Van Cangh
P, Vekemans K, et al.Identification of patients with
prostate cancer who benefit from immediate postoperative
radiotherapy: EORTC 22911. Journal of Clinical Oncology
2007;25:4178–86.
Van der Kwast TH, Collette L, Van Poppel H, Van Cangh
P, Vekemans K, DaPozzo L, et al.Impact of pathology
review of stage and margin status of radical prostatectomy
specimens (EORTC trial 22911). Virchows Archive 2006;
449(4):428–34.
Wiegel T. No negative effect of percutaneous radiotherapy
on continence after radical prostatectomy-the results of
a prospective randomized study [Kein negativer Einflul3
der perkutanen Strahlentherapie auf die Kontinenz nach
radikaler Prostatektomie – Ergebnisse einer prospektiv
randomisierten Studie]. Strahlentherapie und Onkologie
1998;174(10):546–7.
Zurlo A, Collette L, van Tienhoven G, Blank L, Warde
P, Dubois J, et al.Acute toxicity of conventional radiation
therapy for high-risk prostate cancer in EORTC trial 22863.
European Urology. 2002; Vol. 42:125–32.
SWOG {published data only}
Hayden KA, Moinpour CM, Faulkner J, Tangen CM,
Canby-Hagino ED, Lemmon D, et al.Short- and long term
genitourinary symptom status and global quality of life
(QOL) from a Southwest Oncology Group (SWOG) trial.
ASCO Annual Meeting Proceedings in Journal of Clinical
Oncology 2005;23(16S):4556.
Moinpour CM, Hayden KA, Unger JM, Thompson IM,
Redman MW, Canby-Hagino ED, et al.Health-related
quality of life results in pathologic stage C prostate cancer
from a Southwest Oncology Group trial comparing radical
prostatectomy alone with radical prostatectomy plus
radiation therapy. Journal of Clinical Oncology 2008;26(1):
112–20.
Swanson GP, Goldman BH, Tangen C, Thompson IM,
Chin J, Messing E, et al.Lack of low-risk pathologic findings
in SWOG 8794. International Journal of Radiation
Oncology, Biology Physics. 2009; Vol. 75, issue 3:S10.
Swanson GP, Hussey MA, Tangen CM, Chin J, Messing
E, Canby-Hagino E, et al.Predominant treatment failure
in postprostatectomy patients is local: analysis of patterns
of treatment failure in SWOG 8794. Journal of Clinical
Oncology 2007;25(16):2225–9.
Swanson GP, Thompson IM, Tangen C, Paradelo J, Canby-
Hagino E, Crawford ED. Update of SWOG 8794: adjuvant
radiotherapy for pT3 prostate cancer improves metastasis-
free survival. International Journal of Radiation Oncology
Biology Physics. 2008:S31.
∗ Thompson IM, Tangen CM, Paradelo J, Scott Lucia
M, Miller G, Troyer D, et al.Adjuvant radiotherapy for
pathologically advanced prostate cancer. JAMA 2006;296
(19):2329–35.
Thompson IM, Tangen CM, Paradelo J, Scott Lucia
M, Miller G, Troyer D, et al.Adjuvant radiotherapy for
pathological T3N0M0 prostate cancer significantly reduces
risk of metastases and improves survival: long-term follow-
up of a randomized clinical trial. The Journal of Urology
2009;181:956–62.
References to studies excluded from this review
Elias 1997 {published data only}
Elias S, Parker RG, Gallardo D, Law J. Adjuvant
radiotherapy after radical prostatectomy for carcinoma of
the prostate. American Journal of Clinical Oncology 1997;20
(2):120–4.
Jani 2005 {published data only}
Jani AB, Kao J. Postprostatectomy adjuvant versus salvage
radiotherapy: a complication-adjusted number-needed-to-
treat analysis. Cancer 2005;103(9):1833–42.
References to ongoing studies
NCT00667069 {published data only}
NCT00667069. Randomised, multicentred study
comparing the immediate radiotherapy associated with
hormonal therapy of LH-RH analogue (Decapeptyl® LP)
vs delayed radiotherapy until biochemical relapse associated
with hormonal therapy of LH-RH analogue (Decapeptyl®
LP) in patients with operable prostate cancer pT3R1pNo or
pNx at intermediate risk. http://clinicaltrials.gov/ct2/show/
NCT00667069 (accessed 25 August 2010).
RADICALS {published data only}
NCT00541047. RADICALS - Radiotherapy and androgen
deprivation in combination after local surgery. http://
www.clinicaltrials.gov/ct2/NCT00541047 (accessed 19
January 2010).
Parker C, Clarke N, Logue J, Payne H, Catton C, Kynaston,
H et al (The RADICALS Trial Management Group).
RADICALS (Radiotherapy and androgen deprivation in
combination after local surgery). Clinical Oncology 2007;
19:167–71.
Parker C, Sydes MR, Catton C, Kynaston H, Logue
J, Murphy C, Rachel C. Radiotherapy and androgen
deprivation in combination after local surgery
(RADICALS): A new Medical Research Council/National
Cancer Institute of Canada phase III trial of adjuvant
treatment after radical prostatectomy. British Journal of
Urology International 2007a;99:1376–9.
17Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
RAVES {unpublished data only}
NCT00860652. Radiotherapy - adjuvant versus early
salvage. A phase III multi-centre randomised trial
comparing adjuvant radiotherapy (RT) with early salvage
RT in patients with positive margins or extraprostatic
disease following radical prostatectomy. clinicaltrials.gov/
ct2/NCT00860652 (accessed 19 January 2010).
Additional references
Abi Aad 1993
Abi Aad AS, Opsomer RJ, Wese FX, Lorge F, VanCangh
PJ. Objective evaluation of continence after radical
prostatectomy. Journal of Urology. 1993; Vol. 145:235.
Amling 2000
Amling CL, Blute ML, Bergstrahl EJ, Seay TM, Slezak J,
Zincke H. Long-term hazard of progression after radical
prostatectomy for clinically localized prostate cancer:
continued risk of biochemical failure after 5 years. Journal
of Urology 2000;164(1):101–5.
Anscher 2000
Anscher MS, Clough R, Dodge R. Radiotherapy for a rising
prostate-specific antigen after radical prostatectomy: the
first 10 years. International Journal of Radiation Oncology
Biology Physics 2000;48(2):369–75.
Bates 1983
Bates P, Bradley W, Glen E, Melchior R, Rowan D,
Sterling A, Hald T. Fifth report in the standardisation of
terminology of lower urinary tract function. Quantitation
of urine loss. International Continence Society Committee
for Standardisation of Terminology 1983.
Bernard 2010
Bernard JR Jr, Buskirk SJ, Heckman MG, Diehl NN, Ko
SJ, Macdonald OK, et al.Salvage radiotherapy for rising
prostate-specific antigen levels after radical prostatectomy
for prostate cancer: dose-response analysis. International
Journal of Radiation Oncology Biology Physics 2010;76(3):
735–40.
Bill-Axelson 2011
Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark
J, Busch C, et al.for the SPCG-4 Investigators. Radical
prostatectomy versus watchful waiting in early prostate
cancer. New England Journal of Medicine 2011;364:
1708–17.
Bolla 2002
Bolla M, Collette L, Blank L, Warde P, Dubois JB,
Mirimanoff RO, et al.Long-term results with immediate
androgen suppression and external irradiation in patients
with locally advanced prostate cancer (an EORTC study): a
phase III randomised trial. Lancet 202;360(9327):103–6.
Bolla 2004
Bolla M, Van Popple H, Van Cangh P, et al.Does post-
operative radiotherapy after radical prostatectomy improve
progression-free survival in pT3N0 prostate cancer
(EORTC 22911). Proceedings of Americal Society of
Clinical Oncology Journal of Clinical Oncology. 2004; Vol.
23:382 (abstract).
Bolla 2004a
Bolla M, Van Poppel H, Van Cangh P, et al.Post-operative
radiotherapy (P-XRT) after radical prostatectomy (Px)
improves progression-free survival (PFS) in pT3N0 prostate
cancer (PC). International Journal of Radlation Oncology
Biology Physics. 2004a; Vol. 60:S186.
Bolla 2005
Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans
K, Da Pozzo L, et al.Postoperative radiotherapy after radical
prostatectomy: a randomised controlled trial (EORTC
22911). The Lancet 2005;366:572–8.
Bolla 2007
Bolla M, Van Poppel H, Collette L. Preliminary results for
EORTC trial 22911: radical prostatectomy followed by
postoperative radiotherapy in prostate cancers with a high
risk of progression. Cancer Radiotherapie 2007;11(6-7):
363–9.
Burnett 2007
Burnett AL, Aus G, Canby-Hagino ED, Cookson MS,
DAmico AV, Dmochowski RR, et al.Erectile function
outcome reporting after clinically localized prostate cancer
treatment. The Journal of Urology 2007;178:597–601.
Cadeddu 1998
Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long
term results of radiation therapy for prostate cancer
recurrence following radical prostatectomy. Journal of
Urology 1998;159(1):173–7.
Cheung 2005
Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee
AK, Pisters L, et al.Outcome of salvage radiotherapy
for biochemical failure after radical prostatectomy with
or without hormonal therapy. International Journal of
Radiation Oncology Biology Physics 2005;63(1):134–40.
Collette 2005
Collette L, Burzykowski T, Carroll KJ, Newling D, Morris
T, Schröder FH, et al.Is prostate-specific antigen a valid
surrogate end point for survival in hormonally treated
patients with metastatic prostate cancer? Joint research of
the European Organisation for Research and Treatment
of Cancer, the Limburgs Universitair Centrum, and
AstraZeneca Pharmaceuticals. Journal of Clinical Oncology
2005;23(25):6139–48.
Cookson 2007
Cookson MS, Aus G, Burnett AL, Canby-Hagino ED,
D’Amico AV, Dmochowski RR, et al.Variation in the
definition of biochemical recurrence in patients treated
for localised prostate cancer: The American Urological
Association Guidelines for Localised Prostate Cancer
Update Report and recommendations for a standard in
the reporting of surgical outcomes. The Journal of Urology
2007;177(2):540–5.
Cooperberg 2004
Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004:
insights from national disease registries. Oncology (Williston
Park) 2004;18(10):1239–47.
18Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cooperberg 2010
Cooperberg M, Broering JM, Carroll PR. Time trends and
local variation in primary treatment of localized prostate
cancer. Journal of Clinical Oncology 2010;28(7):1117–23.
Cozzarini 2003
Cozzarini C, Fiorino C, Ceresoli GL, et al.Significant
correlation between rectal DVH and late bleeding in
patients treated after radical prostatectomy with conformal
or conventional radiotherapy (66.6-70.2 Gy). International
Journal of Radiation Oncology Biology Physics 2003;55:
688–94.
Cozzarini 2009
Cozzarini C, Montorsi F, Fiorino C, Alongi F, Bolognesi
A, Da Pozzo LF, et al.Need for high radiation dose (> or
= 70 Gy) in early postoperative irradiation after radical
prostatectomy: a single-institution analysis of 334 high-risk,
node-negative patients. International Journal of Radiation
Oncology Biology Physics 2009;75(4):966–74.
Davis 2002
Davis JB, Reiner B, Dusserre A, Giraud JY, Bolla M,
EORTC. Quality assurance of the EORTC trial 22911. A
phase III study of post-operative external radiotherapy in
pathological stage T3N0 prostatic carcinoma: the dummy
run. Radiotherapy and Oncology. 2002; Vol. 64:65–73.
Dearnaley 1999
Dearnaley DP, Khoo VS, Norman AR, et al.Comparison
of radiation side-effects of conformal and conventional
radiotherapy in prostate cancer: A randomised trial. Lancet
1999;353:267–72.
Deeks 2002
Deeks JJ. Issues in the selection of a summary statistic
for meta-analysis of clinical trials with binary outcomes.
Statistics in Medicine 2002;21:1575–1600.
Duchesne 2003
Duchesne GM, Dowling C, Frydenburg M, Joseph D,
Gogna NK, Neerhut G, et al.Outcome, morbidity, and
prognostic factors in post-prostatectomy radiotherapy: an
Australian multicenter study. Urology 2003;61(1):179–83.
Epstein 1996
Epstein JI, PArtin AW, Sauvageot, J, Walsh PC. Prediction of
progression following radical prostatectomy. A multivariate
analysis of 721 men with long term follow-up. American
Journal of Surgical Pathology 1996;20(3):286–92.
Greenland 1985
Greenland S, Robins J. Estimation of a common effect
parameter from sparse follow-up data. Biometrics 1985;41:
55–68.
Han 2003
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein
JI, Walsh PC. Biochemical (prostate specific antigen)
recurrence following radical prostatectomy for clinically
localized prostate cancer. Journal of Urology 2003;169(2):
517–23.
Higgins 2002
Higgins JPT, Thompson SG. Quantifying heterogeneity in
a meta-analysis. Statistics in Medicine 2002;21:1539–58.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327:
557–60.
Higgins 2008
Higgins JPT, Green S (editors). The Cochrane Handbook for
Systematic Reviews of Intervetions. Chichester: John Wiley
& Sons, 2008.
Hu 2006
Hu JC, Elkin EP, Krupski TL, Gore J, Litwin MS. The
effect of postprostatectomy radiotherapy on quality of life:
results from the Cancer of the Prostate Strategic Urologic
Research Endeavor. Cancer 2006;107(2):281–8.
Hull 2002
Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW,
Scardino PT. Cancer Control with radical prostatectomy
alone in 1,000 consecutive patients. Journal of Urology
2002;167:528–34.
Jemal 2010
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010.
CA: A Cancer Journal for Clinicians 2010;60(5):277–300.
Jemal 2011
Jemal A, Bray J, Center M, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA: A Cancer Journal for Clinicians
2011;61(2):69–90.
Jhaveri 1999
Jhaveri FM, Zippe CD, Klein EA, Kupelian PA.
Biochemical failure does not predict overall survival after
radical prostatectomy for localised prostate cancer: 10 year
results. Urology 1999;54(5):884–90.
Karakiewicz 2005
Karakiewicz P, Beanyoun S, Kattan M, Perotte P, Valiquette
L, Scardino P, et al.Development and validation of a
nomogram predicting the outcome of prostatic biopsy based
on patient age, digital rectal examination and serum prostate
specific antigen. Journal of Urology 2005;173(6):1930–4.
Kausik 2002
Kausik SJ, Blute ML, Sebo TJ, Leibovich BC, Bergstrahl
EJ, Slezak J, Zincke H. Prognostic significance of positive
surgical margins in patients with extraprostatic carcinoma
after radical prostatectomy. Cancer 2002;95(6):1215–9.
King 2008
King CR, Kapp DS. Radiotherapy after prostatectomy: is
the evidence for dose escalation out there?. International
Journal of Radiatian Oncology Biology Physics 2008;71(2):
346–50.
Kupelian 1997a
Kupelian P, Katcher J, Levin HS, Klein EA. Stage T1-2
prostate cancer: a multivariate analysis of factors affecting
biochemical and clinical failures after radical prostatectomy.
International Journal of Radiation Oncology Biology Physics
1997;37(5):1043–52.
Kupelian 1997b
Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis
R, Klein E. External beam radiotherapy versus radical
19Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
prostatectomy for clinical stage T1-2 prostate cancer:
therapeutic implications of stratification by pretreatment
PSA levels and biopsy scores. Cancer Journal from Scientific
American 1997;3(2):78–87.
Kupelian 2004
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA,
Reuther AM, et al.Radical prostatectomy, external beam
radiotherapy <72Gy, external beam radiotherapy > or =
72Gy, permanent seed implantation, or combination seeds/
external beam radiotherapy for stage T1-T2 prostate cancer.
International Journal of Radiation Oncology Biology Physics
2004;58(1):25–33.
Maier 2004
Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R,
Pontes JE. Salvage radiation for a rising PSA following
radical prostatectomy. Urologic Oncology 2004;22(1):50–6.
Mantel 1959
Mantel N, Haenszel W. Statistical aspects of the analysis of
data from retrospective studies of disease. Journal of the
National Cancer Institute 1959;22:719–48.
McQuay 1997
McQuay HJ, Moore RA. Using numerical results from
systematic reviews in clinical practice. Annals of Internal
Medicine 1997;126(9):712–20.
Messing 2006
Messing EM, Manola J, Yao J, Kiernan M, Crawford D,
Wilding G, et al.Immediate versus deferred androgen
deprivation treatment in patients with node-positive
prostate cancer after radical prostatectomy and pelvic
lymphadenectomy. Lancet Oncology 2006;7(6):472–9.
Mickalski 2010
Michalski MJ, Lawton C, El Naqa I, Ritter M, O’Meare
E, . Seider MJ. Development of RTOG consensus
guidelines for the definition of the clinical target volume
for postoperative conformal radiation therapy for prostate
cancer. International Journal of Radiation Oncology Biology
Physics 2010;76(2):361–8.
Mirabell 2007
Miralbell R, Vees H, Lozano J, et al.Endorectal MRI
assessment of local relapse after surgery for prostate cancer:
A model to define treatment field guidelines for adjuvant
radiotherapy inpatients at high risk for local failure.
International Journal of Radiation Oncology Biology Physics
2007;67:356–61.
Moinpour 1991
Moinpour CM, Hayden KA, Thompson IM, et al.Quality
of life assessment in Southwest Oncology Group trials. In:
Tchekmedyian NS, Cella DF editor(s). Quality of Life in
Oncology Practice and Research. Vol. 43-9, Williston Park,
NY: Dominus Publishing Company, 1991.
Moinpour 1998
Moinpour CM, savage MJ, Troxel A, et al.Quality of life
in advanced prostate cancer: Results of a randomized
therapeutic trial. Journal of National Cancer Institute 1998;
90:1537–44.
Moinpour 2008
Moinpour CM, Hayden KA, Unger JM, Thompson IM,
Redman MW, Canby-Hagino ED, et al.Health-related
quality of life results in pathologic stage C prostate cancer
from a Southwest Oncology Group Trial comparing radical
prostatectomy alone with radical prostatectomy plus
radiation therapy. Journal of Clinical Oncology 2008;26(1):
112–20.
Morgan 2008
Scott SC, Waldron TS, Eapen L, Mayhew LA, Winquist
E, Lukkac H. Adjuvant radiotherapy following radical
prostatectomy for pathologic T3 or margin-positive prostate
cancer: A systematic review and meta-analysis. Radiotherapy
and Oncology 2008;88:1–9.
NCT00541047
NCT00541047. RADICALS - Radiotherapy and androgen
deprivation in combination after local surgery. http://
www.clinicaltrials.gov/ct2/NCT00541047 (accessed 19
January 2010).
NCT00860652
NCT00860652. Radiotherapy - adjuvant versus early
salvage. A phase III multi-centre randomised trial
comparing adjuvant radiotherapy (RT) with early salvage
RT in patients with positive margins or extraprostatic
disease following radical prostatectomy. clinicaltrials.gov/
ct2/NCT00860652 (accessed 19 January 2010).
NCT00949962
NCT00949962. Post-operative external radiotherapy
combined with concomitant and adjuvant hormonal
treatment versus postoperative external radiotherapy alone
in pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0,
Gleason score 5-10 prostatic carcinoma. A phase III study.
http://clinicaltrials.gov/ct2/show/NCT00949962 (accessed
25 August 2010).
Nudell 1999
Nudell DM, Grossfeld GD, Weinberg VK, Roach M,
Carroll PR. Radiotherapy after radical prostatectomy:
treatment outcomes and failure patterns. Urology 1999;54
(6):1049–57.
Parker 2007
Parker C, Clarke N, Logue J, Payne H, Catton C,
Kynaston H, et al.RADICALS (Radiotherapy and androgen
deprivation in combination after local surgery). Clinical
Oncology 2007;19:167–71.
Parker 2007a
Parker C, Clarke Y, Loguez NJ, Paynex H, Catton KC,
Kynaston H. RADICALS (Radiotherapy and androgen
deprivation in combination after local surgery). Clinical
Oncology 2007; Vol. 19:167–71.
Pazona 2005
Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona
WJ. Salvage radiation therapy for prostate specific antigen
progression following radical prostatectomy: 10 year
outcome estimates. Journal of Urology 2005;174:1282–6.
20Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pilepich 2001
Pilepich MV, Winter K, John MJ, Mesic JB, Sause W,
Rubin P, et al.Phase III radiation therapy oncology group
(RTOG) trial 86-10 of androgen deprivation adjuvant to
definitive radiotherapy in locally advanced carcinoma of the
prostate. International Journal of Radiation Oncology Biology
Physics 2001;50(5):1243–52.
Pilepich 2005
Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov
HB, Movsas B, et al.Androgen suppression adjuvant to
definitive radiotherapy in prostate carcinoma-long-term
results of phase III RTOG 85-31. International Journal of
Radiation Oncology Biology Physics 2005;61(5):1285–90.
Pisanasky 2000
Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute
ML, Buskirk SJ, et al.Radiotherapy for isolated serum
prostate specific antigen elevation after prostatectomy for
prostate cancer. Journal of Urology 2000;163(3):845–50.
Poortmans 2007
Poortmans P, Bossi A, Vandeputte K, et al.Guidelines for
target volume definition in post-operative radiotherapy
for prostate cancer, on behalf of the EORTC Radiation
Oncology Group. Radiotherapy and Oncology 2007;84:
121–7.
Pound 1999
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson
JD, Walsh PC. Natural history of progression after PSA
elevation following radical prostatectomy. JAMA 1999;271
(17):1591–7.
RevMan
The Nordic Cochrane Center, The Cochrane Collaboration.
Review Manager (RevMan). 5.0.22. Copenhagen: The
Nordic Cochrane Center, The Cochrane Collaboration,
2008.
Rodriguez 1988
Rodriguez FR, Thompson IM, Corrie D, et al.[Radical
retropubic prostatectomy: A quality of life survey]. 36th
Annual James C Kimbrough Urological Seminar, Norfolk,
Virginia Oct 31- Nov 4. 1988:Abstract.
Roehl 2004
Roehl KA, Han M, Ramos CG, Antenor JA, Catalona
WJ. Cancer progression and survival rates following radical
retropubic prostatectomy in 3,478 consecutive patients:
long-term results. Journal of Urology 2004;172(3):910–4.
Roque 2008
Roque 2008. Adjuvant radiotherapy for pathologically
advanced prostate cancer : meta-analysis of randomized
controlled trials. Journal of Urology. 2008; Vol. 179, issue
4:183–4.
Rosen 1997
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick
J, Mishra A. The international index of erectile function
(IIEF): a multidimensional scale for assessment of erectile
dysfunction. Urology 1997;49(6):822–30.
Scher 2004
Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small
EJ, Morris M, et al.Eligibility and outcomes reporting
guidelines for clinical trials for patients in the state of a
rising Prostate Specific Antigen: recommendations from
the Prostate Specific Antigen Working Group. Journal of
Clinical Oncology 2004;22(3):537–56.
Sidhom 2008
Sidhom MA, Kneebone AB, Lehman M, Wiltshire KL,
Jeremy L, Millar JL, et al.Post-prostatectomy radiation
therapy: Consensus guidelines of the Australian and New
Zealand Radiation Oncology Genito-Urinary Group.
Radiotherapy and Oncology 2008;88(1):10–9.
Stephenson 2004
Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler
EB, Teh BS, et al.Salvage radiotherapy for recurrent prostate
cancer after radical prostatectomy. JAMA 2004;291(11):
1325–32.
Swanson 2007
Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E,
Canby-Hagino E, et al.Predominant treatment failure in
postprostatectomy patients is local: analysis of patterns of
failure in SWOG 8794. Journal of Clinical Oncology 2007;
25(16):2225–9.
Swanson 2008
Swanson GP, Thompson IM, Tangen C, Paradelo J, Canby-
Hagino E, Crawford ED. Update of SWOG 8794: adjuvant
radiotherapy for pT3 prostate cancer improves metastasis-
free survival. International Journal of Radiation Oncology
Biology Physics. 2008:S31.
Swanson 2009
Swanson GP, Goldman BH, Tangen C, Thompson IM,
Chin J, Messing E, et al.Lack of low-risk pathologic findings
in SWOG 8794. International Journal of Radiation
Oncology Biology Physics. 2009; Vol. 75, issue 3:S10.
Swindle 2005
Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler
T, Maru N, et al.Do margins matter? The prognostic
significance of positive surgical margins in radical
prostatectomy specimens. Journal of Urology 2005;174(3):
903–7.
Thompson 2006
Thompson IM, Tangen CM, Paradelo J, Scott Lucia
M, Miller G, Troyer D, et al.Adjuvant radiotherapy for
pathologically advanced prostate cancer. JAMA 2006;296
(19):2329–35.
Thompson 2009
Thompson IM, Tangen CM, Paradelo J, Scott Lucia
M, Miller G, Troyer D, et al.Adjuvant radiotherapy for
pathological T3N0M0 prostate cancer significantly reduces
risk of metastases and improves survival: long-term followup
of a randomized clinical trial. The Journal of Urology 2009;
181:956–62.
Tombal 2006
Tombal B, Scaillet P, Opsomer R, et al.Immediate external
beam radiation therapy (EBRT) after radical prostatectomy
21Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(PCa): long-term influence on QOL, urinary and rectal
symptoms. American Urological Association: Annual
Meeting. May 20–25, 2006:A1599.
Tomita 2009
Tomita N, Kodaira T, Furutani K, Tachibana H, Nakahara
R, Mizoguchi N, et al.Early salvage radiotherapy for patients
with PSA relapse after radical prostatectomy. Journal
of Cancer Research and Clinical Oncology 2009;135(11):
1561–7.
Valicenti 1998
Valicenti RK, Gomella LG, Ismail M, Mulholland SG,
Petersen RO, Corn BW. Effect of higher radiation dose on
biochemical control after radical prostatectomy for PT3N0
prostate cancer. International Journal of Radiation Oncology
Biology Physics 1998;42(3):501–6.
Van Cangh 1998
Van Cangh PJ, Richard F, Lorger F, et al.Adjuvant radiation
therapy does not cause urinary incontinence after radical
prostatectomy: results of a prospective randomised study.
Journal of Urology 1998;159:164–6.
Van Der Kwast 2006
Van Der Kwast TH, Bolla M, Van Poppel H, et al.Gleason
score and margin status are the strongest predictors for
benefit of radiotherapy after radical prostatectomy. Journal
of Urology. 2006.
Van der Kwast 2006a
Van der Kwast TH, Collette L, Van Poppel H, Van Cangh
P, Vekemans K, DaPozzo L, et al.Impact of pathology
review of stage and margin status of radical prostatectomy
specimens (EORTC trial 22911). Virchows Archive 2006a;
449(4):428–34.
Van der Kwast 2007
Van der Kwast TH, Bolla M, Van Poppell H, Van Cangh
P, Vekemans K, et al.Identification of patients with
prostate cancer who benefit from immediate postoperative
radiotherapy: EORTC 22911. Journal of Clinical Oncology
2007;25:4178–86.
Ward 2003
Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H .
The long-term clinical impact of biochemical recurrence of
prostate cancer 5 or more years after radical prostatectomy.
Journal of Urology 2003;170:1872–6.
Wiegel 1998
Wiegel T. No negative effect of percutaneous radiotherapy
on continence after radical prostatectomy-the results of
a prospective randomized study [Kein negativer Einflul3
der perkutanen Strahlentherapie auf die Kontinenz nach
radikaler Prostatektomie – Ergebnisse einer prospektiv
randomisierten Studie]. Strahlentherapie und Onkologie
1998;174(10):546–7.
Wiegel 2005
Wiegel TD, Bottke N,Willich H-J, Piechota R, SouchonM,
Stoeckle C, et al.Phase III results of adjuvant radiotherapy
(RT) versus “wait and see” (WS) in patients with pT3
prostate cancer following radical prostatectomy (RP) (ARO
96-02/AUO AP 09/95). Journal of Clinical Oncology 2005
Annual Meeting Proceedings. 2005; Vol. 23:16S.
Wiegel 2007
Wiegel T, Bottke D, Willich N, Siegmann A, Stoekle M,
Ruebe C, et al.Phase III results of adjuvant radiotherapy
versus “wait and see” in patients with pT3 prostate cancer.
International Journal of Radiation Oncology Biology
Physics. 2007; Vol. 69, issue 3:S1062.
Wiegel 2007a
Wiegel T, Bottke D, Willich N, Piechoto A, Siegmann M,
Stoekle M, et al.Phase III results of adjuvant radiotherapy
(RT) versus wait-and-see (WS) in patients with pT3 prostate
cancer following radical prostatectomy (RP) (ARO 96-02/
AUO AP 09/95). Journal of Clinical Oncology. 2007a;
Vol. 25:18S.
Wiegel 2008a
Wiegel T. No negative effect of percutaneous radiotherapy
on continence after radical prostatectomy-the results of
a prospective randomized study [Kein negativer Einflul3
der perkutanen Strahlentherapie auf die Kontinenz nach
radikaler Prostatektomie – Ergebnisse einer prospektiv
randomisierten Studie]. Strahlentherapie und Onkologie
1998;174(10):546–7.
Wiegel 2009
Wiegel T, Bottke D, Steiner U, Siegmann A, Golz
R, Störkel S, et al.Phase III postoperative adjuvant
radiotherapy after radical prostatectomy compared with
radical prostatectomy alone in pT3 prostate cancer with
postoperative undetectable prostate-speciifc antigen: ARO
96-02/AOU AP 09/95. Journal of Clinical Oncology 2009;
27(18):2924–30. [: thomas.wiegel@uniklinik–ulm.de
(accessed 23 February 2011)]
Wiltshire 2007
Wiltshire KL, Brock KK, Haider MA, et al.Anatomic
boundaries of the clinical target volume (prostate bed) after
radical prostatectomy. International Journal of Radiation
Oncology Biology Physics 2007;69:1090–9.
Zurlo 2002
Zurlo A, Collette L, van Tienhoven G, Blank L, Warde
P, Dubois J, et al.Acute toxicity of conventional radiation
therapy for high-risk prostate cancer in EORTC trial 22863.
European Urolology. 2002; Vol. 42:125–32.
∗ Indicates the major publication for the study
22Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ARO
Methods Randomised controlled trial, median follow up 53.7 months.
Participants 385 men who have had a radical prostatectomy for prostate adenocarcinoma with pT3-
4N0M0 with positive or negative margins (ie. cancer extending beyond the capsule, into
seminal vesicles or invading other adjacent tissues, with or without positive margins)
Median age 64 (50 to 77). No data re race or comorbidities. Median preoperative PSA:
10.4. Gleason Score (GS) surgical specimen < 6: 32%, 7: 54%, >8: 14%. Positive surgical
margin (PSM): 68%, Seminal vesicle invasion (SVI): 28%
Interventions Experimental arm: (if reached nadir) 60 Gy in 30 # external beam radiotherapy (EBRT)
, if did not nadir, received upfront EBRT
Control arm: if did not nadir EBRT (60 Gy in 30 #), if nadir reached, observed
Outcomes Primary endpoint: biochemical progression free survival. Biochemical progression was
defined as ”two consecutive PSA increases above the detection limit of the assay used“.
Men who did not achieve undetectable PSA were counted as failures from the time of
randomisation
Secondary endpoints: metastasis free survival, overall survival and acute and late toxicity
Notes Central pathology review performed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”We did a randomised trial“ (Ab-
stract 1062, IJROBP 2007)
Quote: ”randomly assigned” p 2925, para
7.
Quote: “using computer generated lists
with permuted blocks of randomly varying
size per stratum” p2925, para 7
Quote: “Patients were stratified for Glea-
son-score, margin status, neoadjuvant hor-
monal treatment and stage (pT3A+B ver-
sus C).” Methods section abstract (Wiegel
2007a, Wiegel 2007). Sequence generation
probably adequate, knowing history of well
organised and established trials group
Allocation concealment (selection bias) Low risk Quote: “We did a randomised trial” Ab-
stract (Wiegel 2007). Quote: ’385 men
with prostate cancer were randomised”
(Materials and Methods section of ab-
23Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ARO (Continued)
stract (Abstract 1062, IJROBP 2007).
Quote: “menwith prostate cancerwere ran-
domised” (Abstract 1062, IJROBP 2007)
Quote: Randomisationwas performed cen-
trally...” p 2925, para 7
Allocation concealed (personal communi-
cation with authors)
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Not mentioned, probably not done.
“Clinical examinations, including digital
rectal examinations, and PSA tests were
done every 3 months for 2 years, then ev-
ery 6 months until the end of the fifth year,
then every year.”
PSA failure: As the time intervals for PSA
tests were pre-specified, lack of blinding
unlikely to contribute to bias. Some risk
if more frequent investigation for distant
metastatic disease in observation arm, but
low risk
Blinding (performance bias and detection
bias)
Subjective outcomes
Unclear risk Patient and assessor blinding: not men-
tioned, probably not done (there is insuf-
ficient information to permit judgement)
. May have had an effect on reporting of
acute and late toxicity
Incomplete outcome data (attrition bias)
All outcomes
High risk 388 men randomised, 3 excluded because
ineligible (1 in control arm received AD, 2
in adjuvant RT arm received AD)
3 different analyses reported -
1) ITT1 - including all patients randomised
according to intention to treat
2) ITT2 - excluding those patients who did
not achieve an undetectable PSA
3) ITT3 - according to treatment actually
received (per protocol analysis)
Adjuvant RT arm n = 194 (includes ineli-
gible 2 receiving AD)
45 excluded because of progressive disease
(PSA did not become undetectable)
34 did not receive RT
148 analysed ITT2
114 analysed ITT3
Control arm n = 194 (includes ineligible 1
receiving AD)
33 excluded because of progressive disease
(PSA did not become undetectable)
5 received postoperative RT
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ARO (Continued)
159 analysed ITT2
154 analysed ITT3
Most concern regarding bias is with ITT3,
because there are large differences in the
proportions of patients excluded from each
arm. The data reported for overall survival
and distant metastases are from ITT2. In
this analysis, those men who did not nadir
were excluded after randomisation. 45/194
(23%) in adjuvant RT arm and 33/194
(17%) in observation arm were excluded
postrandomisation, making these analyses
at high risk of bias. For the outcome of bio-
chemical relapse, data was available for all
randomised men
Selective reporting (reporting bias) High risk Outcomes specified in methods:
Primary endpoint: biochemical progres-
sion-free survival (bNED PFS)
Secondary endpoints: metastasis-free sur-
vival, overall survival, acute and late tox-
icity. These outcomes were reported for
a group which did not include all ran-
domised men, increasing the risk of bias
(Wiegel CJO 27 (18) p 2925, para 10)
Outcomes actually reported in paper:
bNED PFS
distant metastases, deaths.
Toxicity - report % with grade > 1 GI or
bladder adverse effects in each group. Un-
clear whether acute or late. Urethral stric-
ture: 2 in experimental arm, 1 in control
arm
We did not review the study protocol.
Other bias Unclear risk Unclear
EORTC
Methods Randomised controlled trial, median follow up 60 months.
Participants 503 men with pT0-3N0M0 prostate cancer (post radical prostatectomy) with one of:
extra-capsular spread, seminal vesicle involvement or positive margins
Median age 65. No data regarding race. Associated chronic disease in 26.8%. Median
preoperative PSA: 12.3. WHO G1:13%, G2: 63%, G3:24%. PSM: 63%. SVI: 26%
Interventions Experimental arm: EBRT, 60Gy in 30 # (started within 16 weeks of surgery). Control
arm: Observation
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EORTC (Continued)
Outcomes Primary endpoint: biochemical progression-free survival (PFS) (was initially local con-
trol, then changed to clinical PFS, then changed to biochemical PFS). Biochemical PFS
= biochemical progression (increase in PSA > 0.2 ng/mL over the lowest postoperative
value measured on 3 occasions at least 2 weeks apart), or ”clinical progression, or start
of treatment in the absence of progression, if any“
Secondary endpoints: clinical PFS, survival. Toxicity: Acute: (WHOscoring systemused)
Late (EORTC/RTOG scoring system used), Quality of life assessed. Sexual function not
assessed
Notes Biochemical PFS definition: rise of 2ng/dl over nadir on three occasions two weeks apart.
Ten percent of men in all arms did not ever reach nadir. Recommended salvage: 70GY
in 35 # plus or minus LHRH agonist
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “were randomly assigned” (abstract
p 572)
Quote: “were randomly assigned” (Para 4,
page 573)
Probably done (EORTC is known by au-
thors as a rigorous and experienced trials
group)
Allocation concealment (selection bias) Low risk Quote: “Randomisation was centralised at
the EORTC data center. After verification
of all eligibility criteria, a minimisation
technique was used with stratification for
institution, capsule invasion, positive mar-
gins, and invasion of the seminal vesicles.”
(Para 4, page 573)
Probably done, as EORTC is known by the
authors to be an experienced international
trials group
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Not mentioned, probably not done.
Quote: “Clinical examinations with DRE
and PSA test were done at 4, 8 and 12
months after surgery (randomisation), then
every year until death. Chest X-ray and
bone scans were done every year or in case
of clinical or biochemical suspicion of pro-
gression. CT scan and liver ultrasoundwere
used for confirmation of suspected progres-
sion.”
PSA failure: As the time intervals for PSA
tests were pre-specified, lack of blinding
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EORTC (Continued)
unlikely to contribute to bias. Some risk
if more frequent investigation for distant
metastatic disease in observation arm, but
low risk
Low risk of bias in overall survival estima-
tion.
Blinding (performance bias and detection
bias)
Subjective outcomes
Unclear risk Quote: “Local recurrence had to be docu-
mented by DRE (with or without biopsy)
and distant relapse by sonography or scinti-
graphic imaging.”
High risk of bias in determination of local
recurrence (and subsequently also of clini-
cal recurrence, which includes local recur-
rence), particularly considering subjective
nature of interpretation of DRE. Confir-
mation of local recurrence best with biopsy
Some risk of bias in calculation of distant
failure, if more frequent radiological inves-
tigation in men who have not had RT if
clinical symptoms
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk RT arm:
17 ineligible (2 inadequate disease stage, 8
previous or concurrent cancer, 3 prior treat-
ment, 1 lack of baseline data, 3 incomplete
work-up)
Control arm:
20 ineligible (6 inadequate disease stage, 8
previous or concurrent cancer, 2 prior treat-
ments, 3 missing of baseline data, 1 incom-
plete work-up)
No information available about what hap-
pened to people during the course of the
trial, did any go missing?
Experimental arm:
41 switched to wait and see policy (21
refused, 8 postop complications, 10 ad-
vanced disease, 2 unknown)
4 no information
Control arm:
5 switched to postop RT
1 no information
Selective reporting (reporting bias) Unclear risk Pre-specified endpoints:
Primary endpoint:
Initially local control. Amended to ”clinical
progression-free survival in March 1995,
because potential improvement in local
control might benefit clinical progression-
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EORTC (Continued)
free survival“. Amended in April 2003: ”in-
dependent data monitoring committee ac-
cepted biochemical progression-free sur-
vival as primary endpoint (on grounds of
evolving urological practice, to take into ac-
count biochemical relapse as well).”
Although there was a change in primary
outcome from that specified at start of trial,
the new endpoint was specified in amended
protocols, andwas justified. Low risk of bias
as a result of changed primary endpoint
Secondary endpoints:
clinical progression free survival
local recurrence
toxicity (acute and late)
Reported results:
Biochemical progression-free survival. In
protocol authors state deaths without PSA
failure were censored, but clearly included
as event in results
Therapy at salvage
Clinical progression free survival
Loco-regional failure
Distant failure
Overall survival, death due to prostate ca.
Cumulative incidence of late toxicity
Protocol not reviewed
Other bias Low risk Early stopping occurred, based on O’Brien
Flemming rule. The trial was stopped by
the independent data monitoring commit-
tee when the pre-specified P value < 0.02
was reached. They reported the required
sample size (1000) and randomised 1005
men. The treatment effect size was large:
HR 0.48 (95% CI 0.37, 0.62; P < 0.0001)
, this represented 365 events
SWOG
Methods Randomised controlled trial, median follow up 12.5 years.
Participants Dates of data collection: August 1988 to January 1997
Setting: multiple institutions throughout USA and Canada
Inclusion criteria: Men who had RP for prostate adenocarcinoma with extra-capsular
spread, positive margins or seminal vesicle invasion, and no lymph node metastases
detected by pelvic lymphadenectomy (unless ’low risk’*), or distant metastases on bone
scan
*From June 1995 men at low risk of lymph node metastases were not required to undergo
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lymphadenectomy, including: 1) clinical stage T1a or T2a, Gleason score(GS) 2-6, and
PSA < 10 ng/mL, 2) T1b-c, GS 2 to 5 and PSA <10 ng/mL, 3)T2b, GS 2-6 and PSA <
6 ng/mL, and 4) T2c, GS 2-6, and PSA < 4ng/mL
Exclusion criteria: RP >16 weeks from randomisation, total urinary incontinence, in-
traoperative rectal injury, persistent urinary extravasation, pelvic radiotherapy, previous
RT or chemotherapy for prostate cancer
Median age: 65 (observation) and 64 (RT). Race: 72% white, 19% black, 9% other.
No data regarding co-morbidities. Preoperative PSA >10ng/mL: 48% (observation) and
53% (RT). GS <6: 57%, 7: 34%, >8: 9%. Unclear % PSM. SVI 33% (obs) and 32%
(RT).
Interventions EBRT to the pelvic fossa, 60 to 64 Gy in 30 to 32 fractions vs observation
Outcomes Primary endpoint: metastasis-free survival (bony or visceral metastases, extrapelvic nodal
metastases or death from any cause)
Secondary endpoints: biochemical relapse-free (RFS), recurrence free survival (objective
recurrence not including PSA relapse only or death from any cause), time to hormonal
treatment, overall survival, toxicity. Quality of life and sexual function assessed in com-
panion study
Notes Quality assurance conducted. Central pathology review. About 33% of men in both
arms did not achieve undetectable PSA postop
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”central randomisation occurred at SWOG
Statistical Center“
”were randomised“ (abstract)
”S8794 was a randomised multi-institu-
tional study“ (Para 2, page 957)
They have not indicated the method of se-
quence generation, but the trials organisa-
tion is known by the authors to be rigorous
and experienced
Allocation concealment (selection bias) Low risk ”Central randomisation“
”A dynamically balanced method was used
tominimise imbalance in treatment assign-
ment between the levels of the stratification
factors“
”Patients were stratified by extent of tu-
mour (I.e. tumour at inked surgical mar-
gins or beyond the anatomical capsule
and within the seminal vesicle) and by
pre-prostatectomy hormonal use.“ (Para 4,
page 2330)
29Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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Blinding (performance bias and detection
bias)
Objective outcomes
High risk ”Patients and investigators were not
blinded as to treatment assignment“ (Para
4, page 2330)
”Follow-up visits at participating institu-
tions were scheduled every 3 months“
for 1 year, every 6 months for 2 years, and
annually thereafter.”
Quote: “ At each visit, PSA level was ob-
tained, as were additional staging studies (e.
g. bone scans) as clinically indicated”
For primary endpoint (metastasis-free sur-
vival):This is a source of bias, as unblinded
investigators may order bone scans earlier
and therefore introduce lead-time bias, and
shorten metastasis-free survival
PSA relapse-free interval less likely to be bi-
ased by this policy given prespecified inter-
vals for PSA measurement
Death would be unaffected given objective
outcome
Blinding (performance bias and detection
bias)
Subjective outcomes
High risk Quote: “Toxicity monitored weekly during
RT” (Para 3, page 2330)
This is a source of bias, as these patients
having RT had more frequent assessment
of toxicity, and patient and assessors more
likely to report toxicity in RT arm
“Rectal complications and urinary stric-
tures were not graded but were recorded if
annotated on study flow sheets. Total uri-
nary incontinence, while not predefined,
was interpreted as no ability to control
urinary leakage”. Thompson 2006, page
2330, para 5
This is a source of bias, as the recording of
toxicity was not either graded or pre-speci-
ifed, so depends on the interests or biases
of the involved clinician
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “431men enrolled, of thesemen, 425 were
eligible for analysis” (Para 5, page 957) Ac-
cording to ’Figure 1’, 425were randomised,
after exclusion of 6 ineligible patients
“6 ineligible subjects, 2 did not undergo
lymphadenectomy, 2 did not have pathol-
ogy report, 1 had residual disease at bladder
neck and 1 had positive pelvic nodes neck”
(Para 5, page 957)
“all 425 eligible patients were used for each
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SWOG (Continued)
endpoint analysis” (Analysed atmedian fol-
low up of 10.6 years) (Para 2, page 2331)
Quote: “PSA relapse-free interval assessed
in 347/425 men (those with postsurgical
PSA 0.4 ng/mL or lower)” (Para 2, page
2331)
Although many patients were excluded
from the analysis of biochemical failure,
this was prespecified in the protocol, and
probably due to the increased use and avail-
ability of PSA over the time course of the
trial. Table shows similar % in each group
had postop PSA measured, and similar %
(78% control and 83% RT) had postop
PSA <0.4 ng/dL and were included in the
analysis of PSA failure (’Figure 2’). It is un-
likely that the exclusions would cause bias
217/425 men registered to QoL compan-
ion trial.
“Table 2 lists the demographic and clini-
cal characteristics for the HRQOL sample.
Distributions of these are similar for the
two treatment arms and for the HRQOL
sample versus the larger therapeutic sam-
ple”. (Para 10, page 114)
Although there are many exclusions from
QoL analysis, the % and characteristics are
similar in each group, with similar rates of
follow up. Hence unlikely to have intro-
duced bias
Experimental arm:
19 had > 18 months since last contact
4 had < 5 years of follow up
Control Arm:
22 > 18 months since last contact
5 had < 5 years of follow up (’Figure 1’,
page 2331)
Selective reporting (reporting bias) Unclear risk Outcomes specified in methods (protocol
not reviewed)
Primary:
1. Metastasis-free survival
2. Secondary:
3. PSA relapse-free interval
4. Recurrence-free survival
5. Time to hormone therapy
6. Postoperative complications
Outcomes actually reported in paper
1. Metastasis-free survival
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2. PSA relapse-free interval
3. Recurrence-free survival
4. Overall survival (addition of this
unlikely to cause bias as objective
outcome)
5. Time to hormone therapy
6. Postoperative complications
Other bias Low risk None
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Elias 1997 Not RCT
Jani 2005 Not RCT
Characteristics of ongoing studies [ordered by study ID]
NCT00667069
Trial name or title
Methods Open label, randomised controlled trial
Participants DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate pT3a, pT3b (or pT4 by reaching the bladder
neck), or R1 disease (stage III or IV). Localized disease: pN0 or pNx (lymph nodes resected during negative
prostatectomy or lymph nodes not resected). No histologically confirmed nodal involvement during initial
surgery (pN1 disease). No pT2 disease No tumors of other histology than adenocarcinoma
• Must have undergone curative surgery in the past 6 months. Positive margins (tumoral glands in
contact with contour ink)
• No current clinical or biochemical disease. PSA <0.1 ng/mL after prostatectomy (confirmed at 1
month)
• Gleason score < 8 with no seminal vesicles involved
PATIENT CHARACTERISTICS
• ECOG performance status 0 or 1. Life expectancy >10 years. Affiliated with social security program.
No history of cancer within 5 years of surgery except basal cell skin cancer. No known severe hypertension
uncontrolled by appropriate therapy (< 160 mm Hg systolic and/or < 90 mm Hg diastolic). No known
hypersensitivity to gonadotropin-releasing hormone or its analogs. No contraindication of intramuscular
injection. No patients who are deprived of liberty or under guardianship. Not unable to undergo medical
monitoring due to geographical, social, or psychological reasons.
• PRIOR CONCURRENT THERAPY: No prior surgical or chemical castration. No prior hormonal
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therapy. No prior radiotherapy within 3 months after radical prostatectomy. No prior pelvic radiotherapy.
No concurrent participation in another study
Interventions • Arm I (delayed treatment): Patients receive triptorelin intramuscularly on day 1 and then 3 months
later. Patients also undergo conformal radiotherapy daily, 5 days a week, for 7 weeks. Treatment begins at
biochemical relapse (PSA is more than 0.2 ng/mL) and before PSA is more than 2 ng/mL.
• Arm II (immediate treatment): Patients receive treatment as in arm I, but treatment begins within 6
months after surgery.
Outcomes Primary Outcome Measures: Event-free survival (clinical progression, biochemical progression, death) at 5
years
Secondary Outcome Measures: Overall survival
Metastases-free survival
Acute or chronic toxicity
Quality of life
Functional dependence in patients over 75 years old
Starting date
Contact information
Notes Bordeaux, France, 33076
RADICALS
Trial name or title RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
Methods Treatment, Randomized, Open Label, Active Control
Participants Genders Eligible for Study: male
DISEASE CHARACTERISTICS:
Inclusion criteria:
• Diagnosis of nonmetastatic adenocarcinoma of the prostate
• Must have undergone radical prostatectomy
• Postoperative serum prostate-specific antigen (PSA) < 0.4 ng/mL
• No postoperative biochemical failure, defined as EITHER two consecutive rises in PSA and final PSA
> 0.1 ng/mL OR three consecutive rises in PSA (for patients undergoing hormone therapy duration
randomisation)
Exclusion criteria:
• Known distant metastases from prostate cancer
• PSA > 5 ng/mL at the time of hormone randomisation (for patients undergoing hormone therapy
duration randomisation)
PATIENT CHARACTERISTICS:
• No other active malignancy likely to interfere with protocol treatment or follow up
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
• See Disease Characteristics
• Co-enrollment to other trials is permitted, providing this does not interfere with the outcome measures
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• 5-alpha reductase inhibitors, soya, selenium, and vitamin E are acceptable non-trial therapies
Exclusion criteria:
• Prior hormone therapy
• Bilateral orchidectomy
• Prior pelvic radiotherapy
• Neoadjuvant treatment
• Other concurrent therapies for prostate cancer (e.g., estrogens or cytotoxic chemotherapy) prior to
disease progression
Interventions 2X2 randomisation
1) if postoperative uncertainty about the need for immediate radiotherapy, men randomised to
• immediate radiotherapy or
• salvage radiotherapy for PSA failure
Radiotherapy = 66 Gy in 33 fractions over 6.5 weeks to the prostate bed
PSA failure = 2 consecutive rises in PSA and PSA >0.1 ng/mL or 3 consecutive rises in PSA
2) when radiotherapy to be given, men randomised to
• radiotherapy alone
• radiotherapy with 6 months of hormone therapy
• radiotherapy with 2 years of hormone therapy
Hormone therapy = gonadotrophin releasing hormone analogue with 3 weeks of antiandrogen at initiation,
or bicalutamide 150 mg
Outcomes Primary Outcome Measures: Disease-specific survival (i.e., death due to prostate cancer)
Secondary Outcome Measures: Freedom from treatment failure
Clinical progression-free survival
Overall survival
Non-protocol hormone therapy
Treatment toxicity
Patient reported outcomes
Starting date October 2007
Contact information Christopher Parker, MD Royal Marsden NHS Foundation Trust
Notes
RAVES
Trial name or title A Phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in
patients with positivemargins or extraprostatic disease following radical prostatectomy. RAVES (Radiotherapy
Adjuvant Versus Early Salvage)
Methods Design: A two-arm, randomised phase III multicentre, non-inferiority trial.
Patients were stratified according to the following criteria: Pre-operative PSA (as a continuous variable),
Gleason score (from RP specimen; as a continuous variable), surgical margins (positive/negative), seminal
vesicle involvement (pT3b) (yes/no) and radiotherapy institution
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Participants Inclusion Criteria
All of the following must apply
1. Prior Radical Prostatectomy (RP) for adenocarcinoma of the prostate.
2. Histological confirmation of adenocarcinoma of the prostate with the Gleason score reported (Radical
Prostatectomy specimen).
3. Patients must have at least one of the following risk factors:
i) Positive margins
ii) Extraprostatic extension (EPE) with or without seminal vesicle involvement (pT3a or pT3b)
(’Appendix I’)
4. Capable of starting RT within 4 months of RP (a requirement if randomised to adjuvant RT arm)
5. Most recent PSA ≤ 0.1 ng/mL following RP and prior to randomisation
6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 (’Appendix II’)
7. Patient able to adhere to the specified follow-up schedule and complete the Quality of Life and
anxiety/depression self-assessments
8. Written informed consent obtained prior to randomisation
9. Completion of all pre-treatment evaluations
10. 18 years or older
Exclusion Criteria
None of the following must apply:
1. Previous pelvic RT
2. Concurrent or previous malignancy within 5 years prior to randomisation (except non-melanomatous
skin cancer)
3. Androgen deprivation (AD) prior to or following RP
4. Evidence of nodal or distant metastases
5. Co-morbidities that would interfere with the completion of treatment or 5 years of follow up
6. Concurrent cytotoxic medication
7. Hip prosthesis
Interventions Eligible patients will be randomised to either:
Arm A (standard arm) - adjuvant RT commenced within 4 months of RP; or
Arm B (experimental arm) - active surveillance with early salvage RT following a rising
PSA (PSA level >0.2 ng/mL prior to radiotherapy)
Outcomes Primary outcome measure: biochemical failure (bF)
Secondary
1. Secondary objectives will include a comparison of the two treatment arms with respect to each of the
secondary endpoints: QoL, adverse events, anxiety/depression, biochemical failure-free survival, overall
survival, disease-specific survival, time to distant failure, time to local failure, time to the initiation of
androgen deprivation, quality-adjusted life years and cost utility
2. In addition, a prognostic factors analysis will be performed for each time-to-event.
Starting date 30 March 2009
Contact information Dr Maria Pearse
Department of Radiation Oncology
Auckland City Hospital
P.O BOX 92-024
Auckland 1142
New Zealand
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Email: mariap@adhb.govt.nz
Dr Andrew Kneebone
Royal North Shore Hospital
Pacific Highway St Leonards
NSW 2065Tel: +61 2 9926 7483
Fax: +61 2 9906 6833
Email: AKneebone@nsccahs.health.nsw.gov.au
Email: carolfb@adhb.govt.nz
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Adjuvant RT versus nil postprostatectomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 3 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
1.1 Overall survival at 5 years 3 1737 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.03, 0.02]
1.2 Overall survival at 10 years 1 425 Risk Difference (M-H, Fixed, 95% CI) -0.11 [-0.20, -0.02]
2 Metastases 3 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
2.1 Metastases at 5 years 3 1737 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.03, 0.01]
2.2 Metastases at 10 years 1 425 Risk Difference (M-H, Fixed, 95% CI) -0.11 [-0.20, -0.01]
3 Local recurrence 2 1379 Risk Difference (M-H, Fixed, 95% CI) -0.11 [-0.14, -0.08]
3.1 Local recurrence at 5 years 1 1005 Risk Difference (M-H, Fixed, 95% CI) -0.10 [-0.13, -0.06]
3.2 Local recurrence at 10
years
1 374 Risk Difference (M-H, Fixed, 95% CI) -0.14 [-0.21, -0.07]
4 Biochemical relapse ITT1 3 2084 Risk Difference (M-H, Fixed, 95% CI) -0.18 [-0.22, -0.14]
4.1 Biochemical relapse at 5
years
3 1737 Risk Difference (M-H, Fixed, 95% CI) -0.15 [-0.20, -0.11]
4.2 Biochemical relapse at 10
years
1 347 Risk Difference (M-H, Fixed, 95% CI) -0.29 [-0.39, -0.19]
5 Urethral stricture 2 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
5.1 Urethral stricture at 5
years
1 307 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.02, 0.03]
5.2 Urethral stricture at 10
years
1 425 Risk Difference (M-H, Fixed, 95% CI) 0.08 [0.02, 0.15]
6 Urinary incontinence 2 525 Risk Difference (M-H, Fixed, 95% CI) 0.04 [0.01, 0.08]
6.1 Urinary incontinence at 5
years
1 100 Risk Difference (M-H, Fixed, 95% CI) 0.06 [-0.02, 0.15]
6.2 Urinary incontinence at
10 years
1 425 Risk Difference (M-H, Fixed, 95% CI) 0.04 [-0.00, 0.08]
7 Prostate cancer specific survival 1 1005 Risk Difference (M-H, Fixed, 95% CI) -0.01 [-0.03, 0.00]
37Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 1 Overall survival.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 1 Overall survival
Study or subgroup Adjuvant RT No RT
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Overall survival at 5 years
ARO 5/148 8/159 17.7 % -0.02 [ -0.06, 0.03 ]
EORTC 46/502 43/503 57.9 % 0.01 [ -0.03, 0.04 ]
SWOG 20/214 23/211 24.5 % -0.02 [ -0.07, 0.04 ]
Subtotal (95% CI) 864 873 100.0 % 0.00 [ -0.03, 0.02 ]
Total events: 71 (Adjuvant RT), 74 (No RT)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Overall survival at 10 years
SWOG 88/214 110/211 100.0 % -0.11 [ -0.20, -0.02 ]
Subtotal (95% CI) 214 211 100.0 % -0.11 [ -0.20, -0.02 ]
Total events: 88 (Adjuvant RT), 110 (No RT)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Chi2 = 4.59, df = 1 (P = 0.03), I2 =78%
-0.5 -0.25 0 0.25 0.5
Favours adjuvant RT Favours observation
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Analysis 1.2. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 2 Metastases.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 2 Metastases
Study or subgroup Adjuvant RT No RT
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Metastases at 5 years
ARO 4/148 5/159 17.7 % 0.00 [ -0.04, 0.03 ]
EORTC 19/502 18/503 57.9 % 0.00 [ -0.02, 0.03 ]
SWOG 29/214 37/211 24.5 % -0.04 [ -0.11, 0.03 ]
Subtotal (95% CI) 864 873 100.0 % -0.01 [ -0.03, 0.01 ]
Total events: 52 (Adjuvant RT), 60 (No RT)
Heterogeneity: Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Metastases at 10 years
SWOG 93/214 114/211 100.0 % -0.11 [ -0.20, -0.01 ]
Subtotal (95% CI) 214 211 100.0 % -0.11 [ -0.20, -0.01 ]
Total events: 93 (Adjuvant RT), 114 (No RT)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Chi2 = 3.78, df = 1 (P = 0.05), I2 =74%
-0.5 -0.25 0 0.25 0.5
Favours adjuvant RT Favours observation
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Analysis 1.3. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 3 Local recurrence.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 3 Local recurrence
Study or subgroup Adjuvant RT Observation
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Local recurrence at 5 years
EORTC 25/502 74/503 72.9 % -0.10 [ -0.13, -0.06 ]
Subtotal (95% CI) 502 503 72.9 % -0.10 [ -0.13, -0.06 ]
Total events: 25 (Adjuvant RT), 74 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 5.25 (P < 0.00001)
2 Local recurrence at 10 years
SWOG 15/190 40/184 27.1 % -0.14 [ -0.21, -0.07 ]
Subtotal (95% CI) 190 184 27.1 % -0.14 [ -0.21, -0.07 ]
Total events: 15 (Adjuvant RT), 40 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 3.83 (P = 0.00013)
Total (95% CI) 692 687 100.0 % -0.11 [ -0.14, -0.08 ]
Total events: 40 (Adjuvant RT), 114 (Observation)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 6.50 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
-0.2 -0.1 0 0.1 0.2
Favours adjuvant RT Favours observation
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Analysis 1.4. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 4 Biochemical relapse
ITT1.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 4 Biochemical relapse ITT1
Study or subgroup Adjuvant RT No RT
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Biochemical relapse at 5 years
ARO 83/193 100/192 18.5 % -0.09 [ -0.19, 0.01 ]
EORTC 93/502 188/503 48.2 % -0.19 [ -0.24, -0.13 ]
SWOG 44/172 67/175 16.6 % -0.13 [ -0.22, -0.03 ]
Subtotal (95% CI) 867 870 83.4 % -0.15 [ -0.20, -0.11 ]
Total events: 220 (Adjuvant RT), 355 (No RT)
Heterogeneity: Chi2 = 3.39, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 7.05 (P < 0.00001)
2 Biochemical relapse at 10 years
SWOG 60/172 112/175 16.6 % -0.29 [ -0.39, -0.19 ]
Subtotal (95% CI) 172 175 16.6 % -0.29 [ -0.39, -0.19 ]
Total events: 60 (Adjuvant RT), 112 (No RT)
Heterogeneity: not applicable
Test for overall effect: Z = 5.67 (P < 0.00001)
Total (95% CI) 1039 1045 100.0 % -0.18 [ -0.22, -0.14 ]
Total events: 280 (Adjuvant RT), 467 (No RT)
Heterogeneity: Chi2 = 9.02, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 8.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.98, df = 1 (P = 0.01), I2 =83%
-0.5 -0.25 0 0.25 0.5
Favours adjuvant RT Favours observation
41Adjuvant radiotherapy following radical prostatectomy for prostate cancer (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 5 Urethral stricture.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 5 Urethral stricture
Study or subgroup Adjuvant RT Observation
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Urethral stricture at 5 years
ARO 2/159 1/148 100.0 % 0.01 [ -0.02, 0.03 ]
Subtotal (95% CI) 159 148 100.0 % 0.01 [ -0.02, 0.03 ]
Total events: 2 (Adjuvant RT), 1 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 Urethral stricture at 10 years
SWOG 38/214 20/211 100.0 % 0.08 [ 0.02, 0.15 ]
Subtotal (95% CI) 214 211 100.0 % 0.08 [ 0.02, 0.15 ]
Total events: 38 (Adjuvant RT), 20 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 2.51 (P = 0.012)
Test for subgroup differences: Chi2 = 4.88, df = 1 (P = 0.03), I2 =80%
-0.2 -0.1 0 0.1 0.2
Favours adjuvant RT Favours observation
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Analysis 1.6. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 6 Urinary incontinence.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 6 Urinary incontinence
Study or subgroup Adjuvant RT Observation
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Urinary incontinence at 5 years
EORTC 4/48 1/52 19.0 % 0.06 [ -0.02, 0.15 ]
Subtotal (95% CI) 48 52 19.0 % 0.06 [ -0.02, 0.15 ]
Total events: 4 (Adjuvant RT), 1 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 Urinary incontinence at 10 years
SWOG 14/214 6/211 81.0 % 0.04 [ 0.00, 0.08 ]
Subtotal (95% CI) 214 211 81.0 % 0.04 [ 0.00, 0.08 ]
Total events: 14 (Adjuvant RT), 6 (Observation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
Total (95% CI) 262 263 100.0 % 0.04 [ 0.01, 0.08 ]
Total events: 18 (Adjuvant RT), 7 (Observation)
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
-0.1 -0.05 0 0.05 0.1
Favours adjuvant RT Favours observation
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Analysis 1.7. Comparison 1 Adjuvant RT versus nil postprostatectomy, Outcome 7 Prostate cancer specific
survival.
Review: Adjuvant radiotherapy following radical prostatectomy for prostate cancer
Comparison: 1 Adjuvant RT versus nil postprostatectomy
Outcome: 7 Prostate cancer specific survival
Study or subgroup Adjuvant RT Control
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
EORTC 8/502 15/503 100.0 % -0.01 [ -0.03, 0.00 ]
Total (95% CI) 502 503 100.0 % -0.01 [ -0.03, 0.00 ]
Total events: 8 (Adjuvant RT), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. International Incontinence Scale
Grade Definition
0 dry < 1 gm (gram)
no pads
1 minimal 1 to 9 gm
1 to 4 pads (humid)
2 moderate 10 to 50 gm
1 to 4 pads (soaked)
3 severe > 50 gm
with > 4 pads
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Table 2. RTOG/EORTC Late RT score Bladder
0 1 2 3 4
Symptom None Slight
epithelial
atrophy;
Minor
telangiectasia
(microscopic
hematuria)
Moderate
frequency;
Generalized
telangiectasia;
Intermittent
macroscopic
hematuria
Severe frequency and dy-
suria;
Severe generalized telang-
iectasia
(often with petechiae);
Frequent hematuria;
Reduction in bladder ca-
pacity
(< 150 cc)
Necrosis/Contracted
bladder
(capacity <100
cc);
Severe
hemorrhagic
cystitis
Table 3. HQRL - dichotomous measures
Symptom Scale
Tenderness and urgency with bowel movements 1. normal
2. occasionally mild
3. frequently mild
4. mild to moderate
5. frequent, severe urgency, pain, or bleeding
6. had to have a colostomy
Urinary frequency 1. ≤ 4 times/day
2. 5 to 8 times/day
3. 9 to 12 times/day
4. > 12 times/day
5. indwelling catheter
Erectile dysfunction 1. normal
2. weaker
3. insufficient
4. unable
Global HQRL: rating of how life is affected by the state of your
health
1. extremely unpleasant
2. unpleasant
3. moderately unpleasant
4. slightly unpleasant
5. normal (no change)
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Table 4. Definition of nadir
Study Definition of nadir
ARO postoperative PSA < 0.1ng/dL
EORTC PSA < 0.2 ng/dL
SWOG PSA ≤ 0.4 ng/dL
Table 5. Number of men who did not nadir
Study Number of men who did not nadir
ARO 78/388 (20%)
EORTC 108/1005 (10%)
SWOG 127/376 (33%) did not achieve PSA ≤ 0.2 ng/dL
29/376 (7%) of men did not achieve PSA ≤ 0.4ng/dL (which is the definition they used for nadir)
NB: only had PSA information for 376/425 men postoperatively
Table 6. Acute G/U toxicity (RTOG)
Grade Symptoms
0 No change from baseline
1 urinary frequency and nocturia 2 times pretreatment habit, urgency, no medications
2 frequency, urgency and nocturia, medications required
3 frequency urgency and nocturia with spasms and frequent medications required
4 Haematuria requiring transfusion, acute bladder obstruction ulceration/necrosis
5 Death secondary to radiation side effects
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
For MEDLINE, the search strategy will be as follows:
1. randomised controlled trial.pt
2. controlled clinical trial.pt
3. exp randomised controlled trials/
4. exp random allocation
5. exp double blind method/
6. exp single-blind method/
7. 1 OR 2 OR 3 OR 4 OR 5 OR 6
8. (animal not human).sh
9. 7 NOT 8
10. clinical trial.pt
11. exp clinical trial.pt
12. (clin$ adj25 trial$).tw
13. ((single OR double OR triple OR treble) adj25 blind$ or mask$)).tw
14. exp placebos/
15. placebo$.tw
16. Rrandom$.tw
17. exp research design/
18. 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17
19. 18 not 8
20. 9 OR 19
21. exp comparative study/
22. exp evaluation studies/
23. exp follow-up studies/
24. exp prospective studies/
25. (control$ OR prospective$ OR volunteer$).tw
26. 21 OR 22 OR 23 OR 24 OR 25
27. 26 NOT 8
28. 20 OR 27
29. exp prostatic neoplasms/
30. prostatic neoplasms.tw
31. exp Prostatic intrapiethelial neoplasia/
32. prostatic intraepithelial neoplasia.tw
33. exp Carcinoma/
34. carcinoma.tw
35. exp prostate/
36. prostate.tw
37. neoplasm$ or cancer$ or carcinoma$ or neoplasia$ or tumor$ or tumour$ or malignan$
38. 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37
39. NOT 8
40. 28 AND 39
41. exp prostatectomy/
42. prostatectomy.tw
43. 41 OR 42
44. exp radiotherapy/
45. radiation therapy.tw
46. exp chemotherapy, adjuvant/
47. exp neoadjuvant therapy/
48. exp antineoplastic agents, hormonal/
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49. exp androgen antagonists/
50. 44 OR 45 OR 46 OR 47 OR 48 OR 49
51. 43 AND 50
52. NOT 8
53. AND 40
H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 12, 2011
C O N T R I B U T I O N S O F A U T H O R S
TD wrote the protocol, reviewed results of search and abstracts, extracted and checked data and ’Risk of bias’ tables, co-wrote the
discussion and edited review.
BH edited protocol, reviewed results of search and abstracts, extracted and checked data, constructed Risk of bias tables, entered data
into RevMan, analysed data, co-wrote and edited discussion.
ML edited protocol, reviewed results of search and abstracts, edited review.
D E C L A R A T I O N S O F I N T E R E S T
None.
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We reported risk difference not odds ratio as we proposed to do in the protocol (based on peer reviewer’s recommendation).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
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Controlled Trials as Topic; Time Factors
MeSH check words
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